Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Chinyang

Chinyang Chemical Corporation

Premium
Information Technology

Chinyang Chemical is a Korean micro-cap converter of polyvinyl chloride (PVC). It sits inside the KPX/Chinyang group, controlled by the Yang family, and is held 68.2% by Chinyang Holdings. From a single site in Ulsan it calenders and coats PVC into artificial leather, mainly for automotive seats, door trims, consoles and headrests, and into tarpaulin and sheet products. Historically it also made PVC floor coverings. Revenue has fallen from KRW 62.8 bn in FY2011 and KRW 43.3 bn in FY2020 to KRW 18.6 bn in FY2025. The company has reported operating losses every year from FY2021 to FY2025. Its balance sheet, however, is now debt-free and equity-heavy (KRW 39.4 bn equity against KRW 46.2 bn assets at June 2026), and it is anchored by owned industrial land carried at KRW 18.5 bn. The stock trades near 0.9× book. Price moves are driven more by "Oh Se-hoon theme-stock" speculation than by fundamentals. Operating cash flow has been negative for five consecutive reporting periods. --- ### What the company does Chinyang Chemical is a plastics-products manufacturer (Korean Standard Industrial Classification: plastic products manufacturing). It turns PVC resin, plasticizers, stabilizers and textile backings into finished flexible PVC goods. The two main lines in the 2025–2026 filings are: 1. **PVC artificial leather (인조피혁 / "레쟈")**, used mainly in automotive interiors (seats, door trims, consoles, headrests), plus interior/furniture uses and, increasingly, bag applications. 2. **PVC tarpaulin (천막지)**, used for drapery, windbreaks, awnings, simple tents, car shelters, beach umbrellas, livestock-shed covers and general protective covers. Historically, a third line was PVC floor coverings (바닥재) for residential, commercial, healthcare and education buildings. In 2022 the company held a market share above 7% in a domestic flooring market where LX Hausys, KCC Glass and Hyundai L&C together held about 76% (Asia Economy, 13-Jun-2022, citing the DART registration statement). Vendors' descriptions of the current product scope conflict: **Valueline:** (summarising the DART business report, 26.1Q/26.2Q update) names PVC artificial leather and tarpaulin as the main products, with a focus on automotive and interior artificial leather. It does not mention flooring. **IRGO:** still lists "leather and flooring manufacturing" as the main products. **Morningstar:** additionally mentions wallpaper and tent sheets, and eco-friendly thermoplastic olefin (TPO/TOU) products for the automotive and electronics sectors. The company filed a Major Matters Report (Business Suspension / 주요사항보고서(영업정지)) on 27-Dec-2024, together with a temporary trading halt. This would explain why recent business descriptions centre on leather and tarpaulin. ### Business model and revenue model **Product sales: about 98% of revenue:** The company reports a "synthetic resin" (합성수지) segment covering leather, tarpaulin and related PVC goods. Sales are business-to-business, sold to automotive interior vendors (tier-1/tier-2 trimmers) and to distributors and converters for sheet goods (Butler.works segment split, Q2 2026). **Real-estate leasing: about 2% of revenue:** The company leases factory space built on surplus land at its Ulsan headquarters. A plant building on the HQ site was extended on 22-Jun-2021 specifically to build and lease new factory space on idle land (Asia Economy, Jun-2022). Investment property was carried at KRW 5.3 bn at June 2026 (Valueline balance sheet). **Services, subscription or licensing revenue:** none disclosed. ### Value-chain position Chinyang Chemical is a mid-stream converter: **Upstream:** PVC resin and plasticizer producers. The company states that resin and plasticizer are sourced from domestic suppliers, with prices tracking international commodity markets (Valueline, citing DART). **Midstream:** Chinyang Chemical's calendering/coating and finishing at Ulsan. **Downstream:** automotive interior vendors such as Kolon Glotech, which in turn supply Hyundai Motor and Kia. Historically, flooring distributors such as Seokyung SGF were also major customers (Asia Economy, Jun-2022). The company has almost no pricing power in either direction. It buys commodity inputs whose prices it cannot control and sells into concentrated, price-disciplined automotive supply chains. ### Customer types and end-markets | End-market | Products | Customer type | Evidence | |---|---|---|---| | Automotive interiors | PVC artificial leather for seats, door trims, consoles, headrests | Automotive vendors (e.g., Kolon Glotech → Hyundai/Kia). Revenue split: domestic automakers 46%, other automakers 54%. | Valueline (DART); Asia Economy 2022 | | Furniture / interior / marine / bags | PVC leather, including vegan and bio-material variants | Converters, furniture makers | Wisesheets profile; Valueline (DART) | | Construction / renovation (historical; status after 2024 uncertain) | PVC floor coverings | Flooring distributors (e.g., Seokyung SGF) | Asia Economy 2022 | | Industrial / agriculture / leisure | Tarpaulin | Distributors, fabricators | Simply Wall St / Wisesheets profile | | Property | Factory leasing at Ulsan | Industrial tenants | Butler.works (segment 2%) | ### Company's own description vs. independent characterisation **Company description (FY2025 business report, as summarised by Valueline):** The company presents itself as a plastics-products maker carved out of Chinyang Co. in 2001, with headquarters and plant in Ulsan. Its focus is PVC artificial leather and tarpaulin, especially automotive and interior leather. It describes itself as one of the leaders of the domestic automotive PVC leather market alongside LX Hausys and Kolon Industries. It claims advantages in price competitiveness and product development, and is broadening into bags and eco-friendly bio-material products as demand for vegan leather grows. **Independent characterisation:** The company is a sub-scale, single-site PVC converter in structural decline. Revenue has fallen at roughly a 15.6% compound annual rate from FY2020 to FY2025 (derived: KRW 43.3 bn to KRW 18.6 bn). Gross margins are thin (8.8% in FY2025) and the cost base is mostly fixed. Several features dominate the investment case more than the operating business: - owned land and buildings; - equity recently rebuilt through two rights issues (2022 and 2024); - a parent with 68.2% control; - recurring political-theme trading. The "leadership in automotive PVC leather" claim comes from the company and could not be independently quantified.

Revenue$0.0B
Employees37
Market CapN/A
Founded1963
Ulsan, South Korea

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
ChinHung

ChinHung International, Inc.

Premium
Information Technology

ChinHung International is a mid-sized South Korean general contractor, founded in 1959 and listed since 1977, that has been part of the Hyosung Group since its 2008 acquisition and now sits under Hyosung Heavy Industries as the core of that company's construction segment. Its revenue is concentrated in domestic private-sector building work, mainly apartment and mixed-use projects often marketed under Hyosung's "Harrington Place" brand, supplemented by public building contracts (including LH housing) and public civil works such as rail (a 5% share of the GTX-C line) and landfill infrastructure. After a 2011–2018 creditor-led workout, the company rebuilt revenue to KRW 759.4 bn in FY2023, but the downturn in Korean housing pushed it to operating losses in FY2024 and FY2025, driven by provisions on unsold units, PF guarantee losses and litigation. A modest recovery in H1 2026, a rising backlog, and an unresolved six-year sale review by its parent define its current investment case. --- ### What the company does ChinHung International is a domestic general contractor holding the principal Korean general construction licences: civil & architecture works (토목건축공사업), industrial & environmental facilities works (산업·환경설비공사업), and landscaping works (조경공사업), plus a specialty Type-1 gas facilities licence (Sankun licence registry, 2025–2026). It executes projects under three reporting lines the company uses to describe revenue: **Private building (민간건축):** apartments, officetels, mixed-use residential and commercial complexes, redevelopment and reconstruction (도시정비) projects, and factory buildings for private owners. This is the dominant line: 76% of Q2 FY2026 revenue (butler.works, based on the Q2 2026 filing). **Public building (관급건축):** buildings ordered by public bodies, including Korea Land & Housing Corporation (LH) projects. 15% of Q2 FY2026 revenue (butler.works). **Public civil works (관급토목):** roads, rail, landfill and similar infrastructure ordered by public agencies. 9% of Q2 FY2026 revenue (butler.works). ### Business and revenue model Revenue is recognised as construction contract revenue over time (percentage-of-completion), which is standard for Korean contractors. The model is almost entirely project-based contracting; there is no subscription, licensing or recurring service revenue of note. Payment terms on recent disclosed contracts are progress billing (기성불), with no advance payment on the October 2025 Hyosung Heavy contract (DART single-contract disclosure summarised by Digital Today, 28 Oct 2025). Two features distinguish ChinHung's model from a pure third-party contractor: 1. **Group developer–contractor pairing.** Hyosung's management has described a structure in which Hyosung Heavy Industries acts as developer (시행) and ChinHung as builder (시공) on residential projects, which the group credited for the company's improved capability ranking after the workout (Hyosung official quoted by Dealsite, 1 Aug 2019). 2. **Credit support to project financing.** Like most Korean housing contractors, ChinHung provides credit enhancement (completion guarantees, PF guarantees) to developers and trustees. This exposure produced PF guarantee losses in FY2025 (company statement quoted by CEO Score Daily, 12 May 2026). ### Value chain position ChinHung sits in the execution layer of the Korean construction value chain: it wins contracts from developers, trustees, redevelopment associations and public agencies; procures materials and subcontracts specialty trades; and delivers buildings and infrastructure. It does not manufacture materials. ### Customer types and end-markets | Customer type | Examples from disclosures | Source | |---|---|---| | Private developers and trustees | Shinhan Asset Trust (Hyosung Harrington Place Jeju trustee); Samjin General Construction consortium (Daegu Gamsam) | Digital Post, 8 Sep 2025; Economist Korea, 3 Dec 2021 | | Redevelopment / small-scale reconstruction associations | Bupyeong 4 district redevelopment (Incheon); Myeongjang-dong small-scale reconstruction (Busan) | IB Tomato; Dealsite, 6 Jul 2026 | | Group companies | Hyosung Heavy Industries (Changwon circuit-breaker and insulator plant) | DART summary, Digital Today, 28 Oct 2025 | | Public agencies | LH (Oct 2026 contract disclosure); Sudokwon Landfill Site Management Corp.; Korea Rail Network Authority (historical) | chickstockfi DART summary, 13 Oct 2026; eToday 2018; eDaily 2013 | | PPP concessionaires | GTX-C Co. (Seoul metropolitan express rail Line C) | eToday, 2024 | End-markets are domestic residential construction (dominant), non-residential and industrial buildings, and public infrastructure. No overseas operations or revenue were identified. ### Company's own description vs. independent characterisation In public statements, management has described itself as financially stable and as having secured roughly KRW 1 trillion of new orders in each of two consecutive years (company statement reported by Digital Post, 8 Sep 2025). Third-party data providers characterise it as a Hyosung-affiliated housing and civil contractor; one aggregator describes it as relatively civil-heavy, but that characterisation conflicts with the company's own reported mix, in which private building is about three-quarters of revenue (butler.works). **Independent characterisation:** ChinHung is a housing-cycle-exposed mid-tier contractor whose earnings swing with Korean apartment pre-sales, PF conditions and provisioning on legacy projects. Its strategic value lies in its licences, its capability ranking (which qualifies it for larger tenders), its role in the Hyosung residential programme, and, increasingly, construction work tied to Hyosung Heavy Industries' power-equipment capacity expansion.

Revenue$0.4B
Employees481
Market CapN/A
Founded1959
Incheon, South Korea
China

China Crystal New Material Holdings Co., Ltd.

Premium
Information Technology

China Crystal New Material is a Jiangsu-based producer of synthetic mica (fluorophlogopite) and derivative mica products, listed in Korea through a Cayman holding company. It has long described itself as the world's largest producer of synthetic mica. Its product range runs from mica crystal, flakes and wet-ground powders to mica paper, plates and fire-resistant mica tape for cables. These supply pearlescent-pigment makers such as Merck, BASF and Colorray, cosmetics groups such as Shiseido and Intercos, and electrical-insulation markets. Since 2020 the group has bolted on a graphene powder business, which by H1 2026 was the largest single revenue line at 35%. In late 2025 it added an AI software subsidiary. Financially, it combines modest revenue (RMB 353 million in FY2025) with an unusually cash-heavy balance sheet: about ₩335 billion of cash against a ₩39 billion market value. The result is a price-to-book near 0.07x. That valuation reflects deep investor scepticism around governance, capital allocation and the "China discount" applied to Chinese issuers on KOSDAQ. --- ### What the company does The group's industrial core is synthetic mica, a man-made fluorophlogopite crystal. It is produced by high-temperature melt synthesis and then processed into flakes and powders. Compared with natural mica, synthetic mica offers higher purity, whiteness, thermal stability (it withstands much higher temperatures) and freedom from the heavy-metal and child-labour supply-chain issues associated with some natural mica sources. Those properties make it the preferred substrate for premium pearlescent (effect) pigments used in automotive coatings, cosmetics, plastics and inks. They also make it a key input for high-temperature electrical insulation, such as mica paper, plates and fire-resistant cable tapes. Third-party descriptions (Morningstar, S&P Global) group the product range into six categories with more than 100 varieties: - synthetic mica flake - natural wet-ground mica powder - synthetic wet-ground mica powder - cosmetic-grade synthetic wet-ground mica powder - filler-grade synthetic mica powder - fire-resistant synthetic mica tape The current S&P description adds synthetic mica crystal, papers and plates, graphene materials, and downstream products including nacreous (pearlescent) pigments, thermal-insulating and fire-proof materials. End markets named in third-party profiles include: - insulation materials - colour and base cosmetics - automobiles - plastics, paper and home appliances - wire and cable, power generation, insulation board and heat-resistant materials - munitions - aviation, aerospace, metallurgy, electronics, chemicals, textiles, machinery, high-grade inks, fine ceramics and atomic energy ### Company's own description No English-language annual report was located. In Korean press communications the company has repeatedly described itself in four ways: - the world's largest producer of artificial synthetic mica products, with science and technology awards from national, provincial, city and county authorities (Asia Economy, 12 Aug 2025) - the holder of dozens of invention and utility-model patents, with roughly ten technologies, including synthetic mica, at or near international or top domestic level (same source) - a "national high-technology enterprise" and a leading domestic graphene producer (Asia Economy, 22 Aug 2023) - since 2024–2025, a company pursuing an "AI + materials" strategy, which it describes as an "AI-driven materials technology platform" (Asia Economy, 10 Jun 2025 and 1 Jul 2025) ### Business and revenue model The model is overwhelmingly product sales of industrial materials to business customers, priced per tonne or kilogram. - There is no meaningful subscription or licensing revenue. - A small "service-use software" line (7% of H1 2026 revenue, per Butler, which derives its data from DART) appeared after the November 2025 acquisition of GeneVision AI Technology Holdings. That business provides customised solutions built on AI models. It is the only non-product revenue identified. - Graphene powder is sold under multi-tonne supply contracts to industrial users. Examples: Jiangsu Mengde New Material (RMB 60 million, October 2021) and Shanghai Haizhizhu Industrial (rendering; RMB 45 million for 10 tonnes, June 2025). ### Value-chain position The group sits upstream to midstream: 1. It sources raw minerals and, for graphene, graphite oxide. Raw-material control was strengthened in May 2026 by acquiring its graphite-oxide supplier, Wuxi Wanlai Technology. 2. It synthesises mica crystal. 3. It processes the crystal into flakes and powders sold to pigment coaters, cosmetics formulators and insulation converters. 4. It has made intermittent forays downstream: - pearlescent pigments, via the 2022 acquisition of 85% of Lingbao Pearlescent Technology Group (rendering) - mica paper, plates and tapes for insulation, via the 2024 acquisition of 85% of Ping Jiang Material Technology, divested in December 2025 - graphene application products, such as masks and photocatalysts, via the 2021-era acquisitions of Jiangyin Jiayun and Jiangsu Xinjiacheng (renderings) ### Customers and end-markets In October 2023 management named its principal customers as Merck, BASF, Shiseido, Colorray and Intercos (Dealsite, 5 Oct 2023). Pigment majors and cosmetics groups are therefore the anchor accounts for mica powders and flakes. Graphene customers named in disclosures are Chinese industrial firms: Jiangsu Mengde New Material and Shanghai Haizhizhu Industrial. Customer concentration percentages are not publicly disclosed in reviewed sources. ### Independent characterisation Analytically, China Crystal is best understood as a niche specialty-minerals producer with a cash-rich, acquisitive holding-company overlay. **Core economics have deteriorated:** The mica franchise generated operating margins in the mid-20s percent through FY2023. Consolidated operating margin fell to about 15% in FY2025, and gross margin compressed from 41.7% (FY2021) to 30.2% (FY2025) (S&P). **The narrative has shifted repeatedly:** Over 2020–2026 management moved from mica to graphene, then to EV-battery fire protection (2023–2024), then to "AI + materials" (2025–2026). The headline initiative changed about every 18–24 months. **M&A has been round-tripped:** The 2024 Pingjiang acquisition was reversed within 22 months at a lower consideration. **Cash is not returned to shareholders:** The group generated free cash flow of ₩17–50 billion a year (FY2021–FY2025) and paid no dividends. These features, together with the ₩290 billion negative enterprise value, define the investment debate.

Revenue$0.0B
Employees518
Market CapN/A
Founded2003
Jiangsu Province, China
Cheryong

Cheryong Industrial Co., Ltd.

Premium
Information Technology

Cheryong Industrial is a small, debt-free Korean manufacturer of the "hardware layer" of the power grid: metal fittings (금구류) and polymer/synthetic-resin products that hold, join, insulate and protect overhead transmission conductors, distribution lines, underground cable systems, telecom fibre (OPGW) and railway catenary. It was carved out of the Cheryong group in 2011, leaving the transformer business with sister company Cheryong Electric, and it shares that company's chief executive, controlling family and Seoul headquarters. Its revenue is almost entirely domestic and is driven, directly or through the Korea Electrical Industry Cooperative's SME bidding channel, by procurement from Korea Electric Power Corp. (KEPCO). The company has repositioned towards higher-specification products for 345 kV, 765 kV and ±500 kV HVDC lines, which lifted operating margin from 13.9% in FY2024 to 27.9% in FY2025 and to about 31% on a trailing basis by June 2026. It holds roughly KRW 81 bn of cash and short-term deposits against a market value of about KRW 133 bn. --- ### Company's own description (paraphrased from the latest annual report) According to its DART business report, Cheryong Industrial manufactures and sells transmission materials, distribution materials, underground-line materials, telecommunications materials and railway materials, positioning itself as a power and communications infrastructure specialist. It reports two business categories — metal products and synthetic resin products. The metal products category covers fittings for transmission and distribution lines, telecommunications lines and railway catenary systems; the synthetic resin category covers resin products for overhead and underground distribution. Products are made to order on a high-mix, low-volume basis and are supplied directly and indirectly to KEPCO, other domestic public institutions and the private market. The stated management philosophy is to be a market-friendly, technology-leading small-but-strong company (강소기업) focused on product R&D. ### Independent characterisation Cheryong Industrial is best understood as a qualified-vendor component supplier to a near-monopsony utility. KEPCO owns and builds essentially all of Korea's transmission and distribution network, and suppliers must hold vendor qualification and meet KEPCO design standards for each item. Much of Cheryong's volume reaches KEPCO through the Korea Electrical Industry Cooperative (한국전기공업협동조합, KEIC), which bids on KEPCO tenders under SME group-procurement rules using member companies' products; Cheryong assigns all bidding and contracting work to the cooperative, so the cooperative — not KEPCO — is the legal counterparty (DART single sales/supply contract disclosure, 5 Aug 2025). A second channel is unit-price contracts with KEPCO KDN (KEPCO's ICT subsidiary) for OPGW fittings (Smart Today, 14 Mar 2024). The revenue model is 100% product sales; there is no disclosed service, subscription or licensing income other than small rental income from investment property (KRW 0.24 bn per year, FY2025 income statement via Valueline). Revenue is lumpy because large HVDC orders are awarded as discrete tenders with delivery windows of three to five months. ### Value-chain position | Value-chain stage | Cheryong's role | |---|---| | Raw materials (steel, aluminium, zinc for galvanising, copper alloys, polymers/silicone, FRP, recycled plastics) | Purchaser; raw materials were KRW 15.2 bn, or 40% of FY2025 revenue (Valueline cost breakdown) | | Component design and type-testing | In-house R&D institute (Daejeon); joint development with KEPCO KDN | | Manufacturing (forging, casting, machining, galvanising/assembly, polymer moulding) | Okcheon plant; partly outsourced processes not disclosed | | Procurement channel | KEPCO direct tenders, KEIC SME group bids, KEPCO KDN unit-price contracts, railway operators, private EPCs | | Installation | Not performed by Cheryong (done by KEPCO contractors / line construction firms) | | End owner | KEPCO (transmission/distribution), KEPCO KDN (OPGW), railway authorities, telecom operators | ### Customer types and end-markets **Electric utility (dominant):** KEPCO transmission (154 kV, 345 kV, 765 kV AC and ±500 kV HVDC) and distribution (22.9 kV overhead and underground networks). **Utility ICT:** KEPCO KDN OPGW (optical ground wire) projects. **Rail:** catenary tensioning and support equipment for electrified railways. **Civil infrastructure:** special anti-vibration dampers for bridges. **Private market:** industrial and private-network customers (share not disclosed).

Revenue$0.0B
Employees50
Market Cap$0.1B
Founded2011
Seoul, South Korea
Cheryong

Cheryong Electric Co., Ltd.

Premium
Information Technology

Cheryong Electric is a Seoul-headquartered, family-controlled maker of medium-voltage distribution transformers. Since 2022 it has turned from a small, Korea-focused supplier of transformers, switchgear and arresters into one of the most export-dependent Korean beneficiaries of the North American grid-equipment shortage. Revenue rose from KRW 48.8 bn in FY2021 to a peak of KRW 262.7 bn in FY2024, and operating margins approached 38%. In FY2023–FY2024 exports grew to roughly 80–90% or more of sales, almost entirely to US utilities. Transformers make up 100% of revenue. The company's distinguishing features are an unusually lean cost base (about 190 employees), a net-cash balance sheet with effectively zero debt, and niche products such as solid-insulation underground transformers and seismic-resistant cast-resin units. It is now in a cyclical downswing. FY2025 revenue fell 14.7%, and H1 2026 revenue fell roughly 36% year on year as US pricing competition, tariffs and easing distribution-transformer shortages compressed volumes and margins. A newly acquired second Daejeon plant is the company's main bet on the next leg of growth. --- ### What the company does Cheryong Electric designs, manufactures and sells power-distribution equipment, concentrated on distribution transformers. Third-party profiles (Investing.com, Wisesheets, FinancialFilings), which draw on the company's filings, list the following portfolio: - amorphous-core transformers - solid-insulation distribution transformers (SIDT) - oil-immersed transformers - cast-resin (mold) transformers - pad-mounted and pole-mounted transformers - autotransformers - seismic-resistant cast-resin transformers - submersible transformers - solid-insulation overhead transformers - gas-insulated switchgear (GIS) for transmission and distribution and for metro railways - polymer lightning arresters - hybrid cutout switches In practice, the latest half-year disclosure (H1 2026, via Butler) classifies 100% of revenue as transformers. ### Business model and revenue model **Revenue model:** almost entirely product sales, about 100% of revenue. No disclosed service, subscription or licensing revenue. **Order-driven manufacturing:** production is made to order against utility purchase orders and supply contracts. US utilities typically order under framework or supply agreements with call-offs. Domestic sales go largely through KEPCO tenders, often via the Korea Electrical Manufacturers Cooperative. **Cost structure (FY2025, DART via ValueLine):** - Cost of sales was KRW 109.6 bn, or 48.9% of revenue. Raw materials (electrical steel, copper, insulating oil and resin) accounted for KRW 70.1 bn of this. - SG&A was KRW 47.4 bn, or 21.2% of revenue. Freight is the largest SG&A item at KRW 28.5 bn, reflecting trans-Pacific shipment of finished units. - Total labour cost was low: payroll of KRW 15.5 bn was 6.9% of revenue (ETF Shopping, FY2025). ### Value-chain position Cheryong sits mid-chain. It buys grain-oriented electrical steel or amorphous ribbon, copper or aluminium conductors, tanks, bushings and insulating media, and assembles finished distribution transformers. These go to utilities and, domestically, to KEPCO and private customers. It does not produce high-voltage power transformers (the 154–765 kV class made by HD Hyundai Electric, Hyosung Heavy Industries and others). Its US products are reported as pole-mounted and pad-mounted distribution units [low-reliability source: 25–650 kVA range]. ### Customer types and end-markets **US investor-owned utilities:** The largest end-market by far. Public Service Electric & Gas (PSE&G, New Jersey) and Public Service of New Hampshire are named as customers [low-reliability source]. IBK Investment & Securities (February 2025) stated that the US accounts for nearly 100% of the company's exports. **KEPCO and Korean public procurement:** Domestic distribution transformers, plus historically switchgear (GIS) and arresters. **Private domestic customers:** Buildings, industrial sites and railway systems (cast-resin and seismic units, metro-rail GIS). ### The company's own description The company's verbatim annual-report business description was not directly accessed. Its job-board profile (Jobplanet) describes it as a manufacturer specialised in exporting transmission and distribution power equipment. Its 2023 business report, as summarised by Asia Economy (June 2023), said it expected better sales on the back of improving US distribution-transformer export conditions and a continuously rising order backlog. ### Independent characterization Cheryong Electric is best understood as a single-product, single-export-market, high-operating-leverage play on the US distribution-transformer cycle. Its economics in FY2023–FY2024 were exceptional: - operating margins of 37–38% - return on average equity above 49% - capex below 2% of revenue These came from three factors working together: 1. a severe US distribution-transformer shortage that pushed up prices 2. a small, flexible, labour-efficient plant running at 130% utilization (H1 2024, Asia Economy) 3. falling electrical-steel and copper costs in 2023–2024 (Yuanta Securities, March 2024) The same structure makes the company the most exposed listed Korean transformer maker when the cycle turns. Shortages in the distribution class eased by late 2024 (IBK, February 2025). Competitors in Korea, Mexico and the US added capacity. US tariffs added cost. Revenue and margins have fallen sharply since Q4 2024.

Revenue$0.2B
Employees190
Market CapN/A
Founded1986
Seoul, South Korea
Chemtros

Chemtros Co., Ltd.

Premium
Information Technology

| Metric | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Employees (headcount) | — | — | 176 | *Note: Morningstar reports 143 and 151 employees at undated snapshots. Chemtros is a Korean small-cap fine-chemicals manufacturer built on organic synthesis, high-purity purification and, since April 2024, anionic polymerisation. The company is in the middle of a business-model shift. Historically it lived on lithium-ion battery electrolyte additives, industrial and electronic adhesives, display intermediates and pharmaceutical intermediates/APIs. It is now becoming a localised supplier of semiconductor photoresist (PR) materials: KrF polymers, photo-acid generators (PAG), monomers, photosensitive compounds and, increasingly, EUV-generation materials. These are sold mainly to Korean PR formulators and flow through to Samsung Electronics and SK hynix. Semiconductor materials rose from about 10% of sales in 2023 to about 51% in 1H2026, which lifted gross and operating margins to record levels. Chemtros is a second-tier supplier with KRW 57 bn in FY2025 revenue (LTM to June 2026: about KRW 71 bn). Its customers are far larger than it is, its balance sheet has only just been repaired, and its case rests on Korea's push for materials self-sufficiency and on AI-driven HBM and advanced-logic demand. --- ### What the company does Chemtros develops, synthesises, purifies and sells speciality chemical materials to industrial customers. Its activities fall into five product families: (1) semiconductor process materials, chiefly photoresist raw materials (polymers, PAGs, monomers and photosensitive compounds), plus wafer-process materials and cleaning thinners; (2) secondary-battery electrolyte additives (the company's CTW, CTL and CTH series, including a thermal-runaway / fire-prevention additive); (3) display materials and functional intermediates for OLED and LCD; (4) pharmaceutical intermediates and active pharmaceutical ingredients (APIs); and (5) polymer adhesive and sealant materials. The last family covers epoxy adhesives for camera modules and LED TVs, die-attach adhesives, silicone conformal-coating sealants, modified silicone sealants, speaker adhesives and heat-dissipating underfill adhesives (Hankyung, 2025-06-01; Simply Wall St company description; Daum/interview, 2026-06-24). The company also trades merchandise. Craft lists formic acid and xylenes among its products, and merchandise was 18% of 2022 revenue (Hana Securities via Smart Today, 2023-03-29). The company's own recent description, in press releases accompanying its 1H2026 results (13 August 2026), presents Chemtros as an "advanced chemical materials" specialist. It says its semiconductor business centres on PR process materials for the lithography step, built on proprietary synthesis and high-purity purification, and that it has recently extended the line-up to EUV process materials. Management describes semiconductor materials and battery materials as its "two main growth pillars" (Asia Economy and Edaily, 2026-08-13; CEO interview, 2026-06-24). ### Business model and revenue model Chemtros is a pure product business. Revenue comes from B2B sales of manufactured chemicals priced per kilogram or per ton under customer qualification. No service, subscription or licensing revenue was found in any source. The one exception is ODM (original design manufacturing) solutions, which StockHub lists as an activity but which appear to be adhesive formulation work for customers rather than a separate service line; revenue share not publicly disclosed. The model has three economic features: 1. **Consumable, utilisation-linked demand.** Chemtros' materials are consumed in customers' production. Sales therefore track customers' fab and cell-plant utilisation rather than capital spending cycles (ETFShopping company summary). That means volatility when Korean battery cell production stalls, as it did in 2023–2025, and leverage when semiconductor utilisation is high, as in 2026. 2. **Qualification lock-in.** Once a material is designed into a customer's PR formulation or electrolyte recipe, switching suppliers requires requalification. Third-party estimates put this at 2–3 years for battery additives (KoalaGains analysis, 2025-11-28). That creates stickiness but also long sales cycles. 3. **Tiered supply chain position.** Chemtros generally sells to intermediate formulators: PR makers such as Dongjin Semichem and Samsung SDI's electronic materials business, and electrolyte makers. Those formulators in turn supply the end chipmakers (Samsung Electronics, SK hynix) and cell makers (LG Energy Solution, Samsung SDI, SK On) (Hankyung, 2025-06-01; Hana Securities via Smart Today, 2023-03-29). ### Value-chain position In semiconductors, Chemtros sits upstream of PR formulators. It makes the polymer resin, PAG and monomer components that the formulator blends into the finished resist. Japanese companies have historically dominated that layer, which is why the business is framed domestically as "materials localisation". In batteries, it is upstream of electrolyte makers, supplying functional additives. In pharmaceuticals, it supplies intermediates and APIs to Korean drug manufacturers. In adhesives, it sells formulated products directly to electronics module makers. ### Customer types and named customers | End-market | Named customers / channel | Source | |---|---|---| | Semiconductor materials | Dongjin Semichem, Samsung SDI and others (five domestic and overseas customers); end users Samsung Electronics and SK hynix, with Chemtros as a second-tier supplier | Hankyung, 2025-06-01 | | Battery electrolyte additives | Supplied via electrolyte makers to Korea's three major cell makers; SK On and Samsung SDI named | Hana Securities via Smart Today, 2023-03-29; Hankyung, 2025-06-01; Financial News, 2024-02-14 | | Pharmaceuticals (reported) | Daewon Pharmaceutical, Yuhan, Hanmi Pharmaceutical | Hankyung, 2025-06-01 | | Adhesives | Camera module and LED TV makers (unnamed) | Morningstar description | Customer concentration percentages are not publicly disclosed in sources reviewed. Independent analysis characterises concentration as high (KoalaGains, 2025-11-28). ### End-markets served Semiconductors (lithography materials for DRAM, HBM and advanced logic), lithium-ion batteries (EV, IT devices and, increasingly, energy storage systems for AI data centres), displays (OLED/LCD), pharmaceuticals, and electronics assembly (camera modules, TVs, speakers). Under research: water-electrolysis materials and vanadium redox flow batteries (CEO interview, 2026-06-24). ### Independent characterisation Chemtros is best understood as a technology-led contract-style synthesis house in transition to a niche semiconductor-materials specialist. Its competitive asset is process know-how: scaling multi-step organic syntheses and polymerisations from gram-scale laboratory work to tens-of-tons production at the purity the semiconductor industry needs. The CEO himself calls this "completely different technology" from laboratory synthesis (interview, 2026-06-24). Its weaknesses are sub-scale size, dependence on a few domestic formulators who are also potential competitors, a history of missing growth forecasts, and, until January 2026, a stretched balance sheet. The 2024–2026 semiconductor ramp is the first time the company has shown operating leverage at scale. Whether that holds depends on retaining design-ins as customers move to EUV and on Korea's continued policy preference for domestic suppliers.

Revenue$0.0B
Employees176
Market CapN/A
Founded2006
Ansan, South Korea
CHEMTRONICS.

CHEMTRONICS.Co., Ltd.

Premium
Information Technology

CHEMTRONICS is a Korean mid-sized ("중견") electronic-materials and components group. It grew from an industrial-chemical distributor into a diversified supplier to the Samsung-centred electronics ecosystem. It runs four reported businesses. Semiconductor covers 5N ultra-high-purity PGMEA and PGME photoresist solvents and glass-substrate (TGV) processing. Electronics covers TV and appliance PBAs and modules, touch panels, and wireless-charging receivers. It also covers OLED glass etching and thin-glass processing, where Korean press describes the company as the leading domestic specialist. Automotive covers in-vehicle wireless charging, EV charging communication control, camera/SVM, and V2X. Distribution and other covers solvent and paint-raw-material trading plus solar power generation. Wireless charging and automotive sit in listed subsidiary WITS (KOSDAQ: 459100). Revenue reached KRW 637.5 bn in FY2025, but operating margins are thin at 3.6% in FY2025. The equity story now depends on three businesses moving from investment to revenue: semiconductor PGMEA, 8.6-generation IT-OLED etching for Samsung Display, and glass substrates for advanced packaging. --- **What the company does.** CHEMTRONICS combines chemical-process know-how (synthesis, purification, wet etching with hydrofluoric acid) with contract electronics manufacturing. ValueLine Korea summarises the company's own 2Q26 business description as follows: **Semiconductor:** In-house synthesis of 99.999% (5N) PGMEA suited to EUV lithography, and development of TGV (through-glass-via) processing for glass substrates. The company consolidated wafer processor J3 (제이쓰리) in January 2025. **Electronics:** Modules for TVs and home appliances. Touch-screen panels (TSP) and glass for electronic whiteboards, kiosks, and industrial/gaming monitors. Wireless-charging parts for mobile and IT devices. Display-glass etching EMS. **Automotive:** Parts and finished products built on communication-control and image-processing technology. Automotive wireless-charging modules and wired/wireless charging equipment. **Distribution and other:** Trading of paints, coatings, and display chemical raw materials, plus solar electricity generation. **Business model and revenue model.** Revenue is almost entirely product revenue: manufactured goods, processing fees, and traded chemicals. There is no material subscription or licensing income. The mix has three distinct economic models: 1. **Contract manufacturing / ODM** of electronic assemblies for large OEMs (TV/appliance PBAs, wireless-charging modules). High volume, low margin, customer-concentrated. 2. **Process-service (toll processing)** of customer-owned glass. OLED panel slimming and etching, UTG processing, and prospectively TGV glass-substrate processing. Capital-intensive, with high operating leverage to utilisation. 3. **Specialty chemicals and trading.** Proprietary high-purity solvents (PGMEA/PGME/PMA) at the high end; commodity-solvent and paint-raw-material distribution at the low end. **Value-chain position.** CHEMTRONICS is a Tier-2/Tier-1 supplier. In semiconductors it supplies solvent to photoresist makers. Dealsite (May 2026) reports customer approvals at Dongwoo Fine-Chem, Dongjin Semichem, and DuPont, with end users being memory makers. In display it processes mother-glass for panel makers, chiefly Samsung Display. In mobile, WITS is a first-tier Samsung Electronics supplier for wireless-charging receivers (Venture Square, Oct 2024). In automotive it supplies OEMs and infrastructure integrators (KG Mobility, Hyundai AutoEver, SK Telecom consortium). **Customer types and end-markets.** Customers include memory and foundry fabs (indirectly via photoresist makers), OLED panel makers, smartphone and wearable OEMs, TV and appliance OEMs, automakers, Korean public C-ITS/smart-road programmes, and industrial paint and coatings users. KoalaGains states that the primary UTG processing customer is overwhelmingly Samsung Display. **Independent characterisation.** CHEMTRONICS is best described as a low-margin, Samsung-linked conglomerate-in-miniature that is being re-rated as a semiconductor-materials company. Roughly four-fifths of 2Q26 revenue (Electronics 51% plus Distribution/Other 28%, per Butler) comes from businesses with structurally thin margins. The stock is valued on the 15% semiconductor slice and on display/glass optionality. FY2025 operating profit fell 37.8% to KRW 23.2 bn on 10.8% revenue growth (Butler). This shows that new-business start-up costs currently outweigh revenue gains.

Revenue$0.4B
Employees634
Market Cap$0.2B
Founded1983
Sejong Special Self-Governing City, South Korea
ChemOn

ChemOn Inc.

Premium
Information Technology

CorestemChemon is a small-cap Korean "hybrid" biotech that pairs a revenue-generating non-clinical CRO (the former ChemOn, founded in 2000 as Korea's first private GLP safety-testing laboratory) with a high-risk stem-cell drug developer (the former Corestem). The CRO division performs toxicology, safety pharmacology, efficacy and bioanalytical studies for drug, biologic, medical-device, food and chemical developers, historically running 1,000–1,500 studies per year, and supplies essentially all group revenue. The drug division's sole marketed product, NeuroNata-R (lenzumestrocel), is an autologous bone-marrow mesenchymal stem-cell therapy for ALS conditionally approved in Korea in 2014; its global Phase 3 missed its primary endpoint in December 2024, but Korea's MFDS approved a narrowed label for slow-progressing patients in May 2026. The company is loss-making (FY2025 operating loss KRW 21.2 bn on revenue of KRW 20.2 bn), thinly capitalised, and its equity story hinges on CRO recovery and a US BLA targeted for 2027. --- ### Company's own description In its investor materials CorestemChemon describes itself as a "Total Health Care Company" possessing a full-cycle drug-development system — from early non-clinical experimentation through Phase 1–3 clinical capability — with a stated vision of improving quality of life through new-drug development (IR decks, April/June 2024). The company frames the 2022 merger around three pillars: an in-house non-clinical database spanning early experiments to Phase 3 entry, financial stabilisation via the CRO's recurring revenue, and scientific synergy between the CRO's testing infrastructure and the stem-cell pipeline. In its FY2025 business report (as summarised by IB Tomato, April 2026), the company attributes the revenue decline to reduced CRO testing orders amid a global downturn and a prolonged slump in Korea's bio-industry, and to the suspension of NeuroNata-R manufacturing after Q1 2025 pending new-site certification and a label-change application. ### Independent characterisation Functionally, CorestemChemon is a Korean non-clinical CRO carrying a binary stem-cell option: **Economic engine:** The CRO division (former ChemOn) is a fixed-cost-heavy service business — GLP facilities, specialist toxicologists and pathologists, animal husbandry — whose gross margin swings sharply with utilisation. thebell (Sep 2026) notes that when utilisation is low the cost-of-sales ratio exceeds 100%, but incremental revenue drops largely to gross profit. In Q1 2026 the cost-of-sales ratio was 136%; in Q2 2026 it improved to 102.5%. **Option value:** NeuroNata-R is an autologous, intrathecally administered cell therapy for ALS with ~400+ patients treated in Korea since 2014 (Money Today, Jun 2026). Its value depends on (i) domestic commercial restart from the new Osong plant and (ii) a US path via FDA Type C → RMAT → BLA. **Balance-sheet constraint:** Cash of only KRW 2.1 bn at end-FY2025 against KRW 24.1 bn of borrowings due within a year (IB Tomato, Apr 2026) makes the CRO recovery an existential, not merely incremental, variable. ### Revenue model | Revenue type | Description | Share of revenue | Source | |---|---|---|---| | Contract research services (fee-for-study) | Non-clinical safety/efficacy studies billed per contract, recognised over time by percentage of completion | 98% of H1 2026 revenue (KRW 9.5 bn of 9.7 bn); ~98% of FY2025 | thebell Sep 2026; IB Tomato Apr 2026 | | Product sales (cell therapy) | NeuroNata-R manufactured per patient (autologous) and sold in Korea | ~1% of FY2025 (≈KRW 0.2 bn); ~4% of FY2024 (≈KRW 1.1 bn); 13% in FY2019 (pre-merger consolidated) | IB Tomato; SK Securities 2020 | | Licensing / technology transfer | Historically minimal (1% in FY2019); management cites prospective pre-approval out-licensing of NeuroNata-R as a contingent funding source | ~0% currently | SK Securities 2020; IB Tomato | | Government R&D grants | National project funding (≥KRW 5.4 bn secured in 2026) — booked within CRO activity | Included in CRO orders | thebell Sep 2026 | | Subscription | None | 0% | — | ### Value-chain position, customers and end-markets **Value chain:** The CRO sits between discovery/lead optimisation and first-in-human trials, generating the GLP safety package required for IND/CTA filings. Through a 2021-era MOU with clinical CRO Dream CIS (signed by then-ChemOn CEO Song Si-hwan), ChemOn positioned itself to offer an integrated non-clinical-to-clinical service (Daily Pharm). **Customer types:** Korean pharma and biotech developers, medical-device makers, functional-food and cosmetics-ingredient developers, chemical registrants, government research programmes, and — increasingly — overseas institutions (a contract with a Vietnamese university hospital in 2026). **Substance mix:** The September 2024 IR deck's chart of studies by test-article type shows the largest single category at 46.5% of studies (understood to be synthetic pharmaceuticals), with the balance across biologics, chemicals, food/health-functional food, cosmetics, natural-product drugs, medical devices and nanomaterials (0.2%). Exact mapping of the remaining percentages could not be reliably extracted. **End-markets:** Korean drug and device R&D (dominant); emerging adjacent-industry testing (functional foods, cosmetics materials); ALS therapeutics (drug division).

Revenue$0.0B
Employees391
Market CapN/A
Founded2003
Seongnam, South Korea
Cheilbio

Cheilbio Co., Ltd.

Premium
Information Technology

Cheilbio is a small, founder-built Korean manufacturer of veterinary medicines and feed additives, established in 1977 by a Seoul National University veterinary graduate and incorporated in 1989. Its portfolio spans functional feed additives, therapeutic drugs (antibiotics, antimicrobials, parasiticides, disinfectants), fermentation-based products (probiotics, enzymes, yeast culture) and diagnostic kits for cattle, pigs, poultry, aquaculture and pets. Revenue peaked near KRW 39.5bn in FY2014 and has since contracted to KRW 14.4bn in FY2025, with operating losses every year from FY2020 to FY2025. Since 2023 the company has been defined less by its products than by a family control dispute between the founder and his eldest daughter, criminal complaints (all later closed without indictment), two consecutive audit-opinion disclaimers, and a KRX delisting in February 2026 that a court has since ruled void at first instance. The business retains a cash-heavy, low-liability balance sheet, which is the core of its residual value case. --- ### Company's own description The FY2024 business report (filed with KIND on 7 April 2025) describes Cheilbio as a company established in January 1977 whose principal business is the manufacture of veterinary medicines and feed additives. The report classifies all activity under a single business segment, "animal drug manufacturing" (동물약품제조업). FnGuide's company summary, drawn from company filings, characterises the business as research, development, manufacturing and sale of fermentation-based animal drugs, alongside commercialisation of R&D results in product formulation and general feed additives. Morningstar's profile lists the offering set as antibiotics, antimicrobials, lactobacillus (probiotic) products, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, diagnostic kits (ELISA test kits, virus test kits and DNA kits) and feed additives, used for cattle, pigs, chickens, pets and other animals. Simply Wall St groups the range into nutrients/immune products, probiotics, functional products, antibiotics/antibacterials, anthelmintics/anticoccidials, kits, and disinfectants, serving poultry, swine, cattle, fisheries and pets. ### Independent characterisation Cheilbio is best understood as a sub-scale, domestically focused, mid-value-chain formulator and manufacturer. It converts purchased active ingredients and raw materials (the factory registry lists vitamins and antibiotics as principal raw materials) into finished veterinary drugs and feed additives at its Ansan plant, and it also manufactures fermentation-derived ingredients from in-house technology dating to 1990. It does not appear to own proprietary new chemical entities; the one product line described in detail in the FY2024 filing, a florfenicol injectable, competes head-to-head with a rival using the same originator-sourced raw material. **Business model and revenue model.** Revenue is almost entirely product sales (manufactured products plus some traded merchandise). There is no disclosed service, subscription or licensing revenue. The FY2024 filing splits sales by channel as follows: feed-mill and special sales (50.10%), field sales to farms, veterinarians and distributors (34.25%), and exports (15.65%). **Value chain position.** Upstream: purchases APIs (e.g., florfenicol of Novartis origin is implied by the filing's competitive note), vitamins and other inputs. Midstream: formulation, fermentation, and packaging at a KVGMP-type animal drug plant. Downstream: sells to (i) feed manufacturers who incorporate additives into compound feed, (ii) field channels (veterinary distributors and producers), and (iii) overseas distributors. **Customer types.** Feed mills and integrators; livestock and poultry farms; veterinary distributors/clinics; aquaculture; companion-animal channels; export distributors. **End-markets.** Korean livestock production (swine, poultry, cattle), aquaculture, and companion animals; selected export markets. A 2015 profile (Etoday) cited exports to 18 countries including China, Indonesia, Vietnam, Japan, Thailand and Taiwan; the current country list is not publicly disclosed. **Revenue mix by nature (FY2024, derived from KIND excerpt):** manufactured products KRW 10,395.1M (74.7%); merchandise and other KRW 3,512.7M (25.3%, derived as the residual to total revenue).

Revenue$0.0B
Employees42
Market CapN/A
Founded1977
Yongin, South Korea
Cheil

Cheil Grinding Wheel Ind. Co., Ltd.

Premium
Information Technology

Cheil Grinding Wheel is one of South Korea's longest-established manufacturers of bonded abrasives. It produces grinding, cutting and finishing wheels from its Pohang plant and, through production-and-sales subsidiaries, in Indonesia and Vietnam. The company states it manufactures more than 150,000 specifications across vitrified, resinoid, rubber, epoxy, magnesia, CBN and diamond bonds, sold largely under the K-PRIX brand. Conventional abrasive wheels provide about 93% of sales and CBN superabrasive wheels about 6%. Its customers are concentrated in Korea's heavy-industry core: steel (POSCO, SeAH Besteel), automotive (Hyundai Motor) and shipbuilding (HD Hyundai Heavy Industries, Samsung Heavy Industries, Hanwha Ocean). The business is a mature, consumables-driven franchise with revenue of KRW 79–85 bn and single-digit operating margins. It has an effectively debt-free balance sheet holding KRW 34 bn of cash, and it is controlled by the founding Oh family. Since 2025 the equity story has been driven by capital returns more than growth: a tax-free KRW 721 dividend and a KRW 15.5 bn treasury-share cancellation. --- ### Company's own description In its DART business reports and the summaries derived from them, the company describes itself as a specialist manufacturer of grinding stones (연마지석). It produces and sells two product families. Conventional (general) abrasive wheels are used for grinding work in steel, automotive, machinery and shipbuilding. CBN abrasive wheels serve high-performance grinding suited to high rotational speeds. The company says it maintains long-standing trading relationships with major conglomerates including POSCO, Hyundai Motor, SeAH Besteel, Hyundai Heavy Industries, Samsung Heavy Industries and Daewoo Shipbuilding & Marine Engineering (since renamed Hanwha Ocean). It operates a plant in Pohang, production-and-sales subsidiaries in Indonesia and Vietnam, and an in-house technical research institute focused on new-product development and quality improvement. (Source: DART business report summary via ValueLine, updated for 2Q26.) In its English-language trade-fair material, the company says it has been manufacturing grinding-wheel products since 1955 for a wide range of industrial grinding, cutting and finishing applications. It cites more than 150,000 specifications across vitrified, resinoid, rubber, epoxy, MgO, CBN and diamond wheels, and says the K-PRIX brand, introduced in 1984, built an international reputation for its combination of quality, cost and service. (Source: Intec Leipzig exhibitor press release, 28 Nov 2024.) ### Independent characterisation | Revenue type | Share of revenue | Basis | |---|---|---| | Product sales — conventional abrasive wheels (manufactured and traded) | Approx. 93% | 2Q26 segment mix (Butler, from DART) | | Product sales — CBN abrasive wheels | Approx. 6% | 2Q26 segment mix | | Other | Approx. 1% | 2Q26 segment mix | | Services / subscriptions / licensing | Not disclosed; presumed immaterial | — | | End-market | Representative customers named by the company | Typical applications | |---|---|---| | Steel (integrated and special steel) | POSCO, SeAH Besteel | Slab and billet conditioning, roll grinding (including on-line roll grinding), snagging, cut-off | | Automotive and powertrain | Hyundai Motor | Crankshaft and camshaft grinding (conventional and CBN), centerless grinding, gear grinding | | Shipbuilding and heavy engineering | HD Hyundai Heavy Industries, Samsung Heavy Industries, Hanwha Ocean (formerly DSME) | Weld-bead removal, plate finishing, cut-off, depressed-centre and flexible discs | | General machinery, bearings and tooling | Not named | Bearing-ring grinding, tool and knife sharpening, needle grinding, honing | | Rail | Not named | Rail grinding and rail cut-off wheels | | Display / glass / composites | Not named | LCD glass grinding wheels, CFRP machining | | Export distributors and MRO | Not named | Standard wheels, discs and sandpaper products | Cheil Grinding Wheel sits in the middle of the abrasives value chain. It buys abrasive grain (fused alumina, silicon carbide, and CBN/diamond superabrasive grit), bonding systems (phenolic resins, feldspar and clay frits, rubber, epoxy, magnesia) and reinforcement materials. It then mixes, presses, cures or sinters, finishes, balances and tests wheels for industrial users. It does not produce primary abrasive grain, which caps its gross margin in the low-20s percent range (FY2021–FY2025 gross margin 20.6%–23.9%). The company describes two process routes. Resin-bonded wheels are made by the "Bakelite method": mixing, pressing and drying, then curing at about 180°C in electric ovens. Vitrified wheels are mixed, pressed and dried, then sintered at about 1,300°C in kilns using feldspar and clay bond systems. (Source: Intec exhibitor release, Nov 2024.) **Revenue model.** Revenue is almost entirely product sales of consumable abrasives. Wheels wear out in use, which generates recurring replacement demand tied to customers' production volumes, not to their capital spending. Service or licensing revenue is not disclosed and is presumed immaterial. The balance sheet also shows merchandise inventory of KRW 5.1–5.5 bn (FY2024–FY2025), which indicates a traded-goods line: resale of third-party products such as abrasive-adjacent consumables, safety equipment (gloves, masks, dust suits) and balancing equipment. **Customer types and end-markets** Source: customer names from the DART business report summary (ValueLine); applications from the product catalogue (Investing.com company description). **Geographic reach.** The company exports to Asia, the Middle East, Oceania, Canada, the United States, Central and South America, Europe and Africa (Investing.com company description).

Revenue$0.1B
Employees55
Market CapN/A
Founded1955
Pohang, South Korea
Cheil

Cheil Electric Co., Ltd.

Premium
Information Technology

Cheil Electric is a 70-year-old Busan-based maker of low-voltage electrical distribution and wiring equipment. In practice it runs two businesses. The first is a domestic building-products business. It supplies switches, outlets, smart (home-network-linked) wiring devices, residential distribution panels, circuit breakers and magnetic contactors to Korean construction companies and public housing developers such as LH and SH, plus a dealer network. The second is an export contract-manufacturing business. It builds printed circuit board assemblies (PCBAs) for arc-fault (AFCI) and ground-fault (GFCI) circuit breakers, sold almost entirely to Eaton in the United States. The Eaton relationship dates to 1988. PCBA exports historically made up roughly 40–50% of revenue. Cheil is a small-cap (≈₩140bn market value, ≈₩196bn FY2025 revenue) with low single-digit-to-high-single-digit operating margins. It is owner-controlled and has no regular sell-side coverage. Its equity story depends on Eaton's North American residential and smart-breaker demand and on Korean housing completions. --- ### What the company does Cheil Electric designs, manufactures and sells low-voltage electrical equipment for buildings, and contract-assembles electronic sub-assemblies for a US circuit-breaker OEM. The company's product families, per its 2021 IR deck and broker reports, are: 1. **AFCI/GFCI PCB Assemblies (PCB ASSY).** Detection boards that sense arc faults and ground faults inside circuit breakers. Sold under an exclusive OEM arrangement to Eaton for arc-fault, ground-fault and combination breakers. A newer product line is the PCBA for Eaton's "Smart Breaker 2.0". Joint development began in June 2023 and mass production was pulled forward to 1H 2025. 2. **Smart wiring devices.** Switches and outlets linked to apartment home-network systems, allowing remote control and remote monitoring. The company claims No. 1 domestic market share in this category (company claim; 2021 IR deck). 3. **Conventional wiring devices.** Outlets and switches that connect appliances and cut supply. 4. **Smart distribution boards (smart panel boards).** Household-level integrated power control with real-time metering and automatic control. 5. **Circuit breakers.** Earth-leakage and moulded-case breakers that cut lines on overload, short circuit or ground fault. 6. **Magnetic switches / contactors.** 7. **Merchandise (상품).** Purchased finished goods, including wiring devices, resold through its channels. 8. **Energy-saving "Green New Deal" line-up.** Standby-power auto-cutoff switches, master (batch) light-off switches, and smart distribution boards. Per the 2021 IR deck this line-up was 61% of domestic sales. 9. **Development-stage items.** An "AI smart care system" (presented in 2021 as a next-generation growth product) and AFCI applications beyond homes, such as ESS, solar and EV charging (Finance Scope, Nov 2024). ### Company's own description The company's investor materials (Nov 2021 IR deck, under the former name) describe it as a smart-home core component company. Its vision was to become the global best company in smart wiring devices. It cited automated production lines and cost-reduction investment as the basis for price and sales competitiveness. When it adopted the new name in March 2024, the company said the new name and CI were intended to express, more concisely and clearly, its commitment to innovating home living in the ICT-convergence era (paraphrased from SmartToday, 29 Mar 2024). The latest annual report (FY2025, filed 23 Mar 2026) could not be read directly. Its verbatim business description is therefore not reproduced. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue model | ~100% product sales. No material service, subscription or licensing revenue disclosed. Merchandise resale is ~15–20% of revenue | | Export model | Build-to-print/joint-development OEM contract manufacturing (PCBA) for Eaton, under multi-year sole-source contracts. Yuanta (Sep 2024) described a roughly five-year contract cycle with renewal expected in Dec 2024. The outcome of that renewal was not publicly confirmed by the company | | Domestic model | Specification-driven project sales to construction companies (e.g., GS E&C contract Jan 2022–Feb 2026, ₩16.7bn per Yuanta's contract table) and public housing agencies (LH, SH), plus a national dealer network | | Value-chain position | Tier-1 component supplier to a global electrical OEM (export). Tier-1 building-products supplier to general contractors (domestic) | | Customer types | Global electrical OEM (Eaton), Korean general contractors, public housing corporations, electrical wholesalers/dealers. Schneider Electric is a sales collaborator in Korean premium/special segments such as luxury housing and hotels, and Cheil distributes Schneider UPS locally (2021 IR deck) | | End-markets | US residential construction and renovation (AFCI mandated in US homes under the NEC since 2002). US smart-home/energy-management (Eaton–Tesla Powerwall project). Korean apartment construction and redevelopment. Korean public housing | ### Independent characterisation On the numbers, Cheil Electric is better described as an export EMS-type subcontractor with a captive customer, attached to a domestic electrical building-products business, than as a "smart-home" company. Three features follow from this structure: **Customer concentration:** One customer accounts for roughly half of revenue. **Opposite drivers:** The export half is driven by US housing and Eaton's sourcing decisions, which are USD-linked. The domestic half is driven by Korean apartment pre-sales and completions with a 2–3 year lag, which are KRW-linked. **Margin compression:** Operating margins fell from 11–13% in FY2019–FY2020 to 5–6% in FY2022–FY2025. The likely drivers are Korean construction weakness, component cost inflation (semiconductor shortages were flagged by Yuanta in 2021) and price pressure. The company has not given a granular margin bridge.

Revenue$0.1B
Employees258
Market CapN/A
Founded1955
Busan, South Korea
Charm

Charm Engineering Co., Ltd.

Premium
Information Technology

Charm Engineering is a former leader in flat-panel display (FPD) repair equipment. The company localised laser repair systems in Korea in 2002 and, by its own account in 2020, held roughly 70% of the global display-repair equipment market. It has since become, in economic substance, a holding vehicle for a regional savings bank. In FY2025 Charm Savings Bank, based in Daegu, generated about 90% of consolidated revenue (KRW 53.4 bn of KRW 59.8 bn). Standalone (non-financial) sales fell to KRW 5.2 bn and domestic headcount to 26. Control passed in 2022 to the Hanbit Asset Management Loan group, a debt-collection and NPL specialist. That group's apparent strategic interest is the savings bank, not the equipment business. Since 2023 the company has posted three consecutive years of heavy losses and completed two capital reductions. It is attempting a pivot into scrap-metal trading. KRX has ruled that it no longer meets listing standards, and continued listing now depends entirely on the court outcome. --- ### Company's own description (FY2025 business report, as summarised by data providers) The company describes itself as a manufacturer of repair equipment that fixes defects arising during display-panel production. Its tools use precision optics, lasers and ink modules and cover LCD, OLED, QD-OLED and micro-LED panels. Two operating segments are reported: **Domestic business:** manufacture and sale of display-panel repair equipment. **Overseas business:** supply of parts and equipment maintenance services to overseas customers of the repair systems, principally in mainland China and Vietnam. (Source: MarketScreener/Zonebourse company description based on the latest annual report.) Separately, the consolidated statements include the savings-bank (financial) business of Charm Savings Bank, which now dominates revenue. In July 2025 the articles of incorporation were amended to add ferrous and non-ferrous scrap processing and sales, and the company began recognising small amounts of scrap revenue in late 2025 (Dealsite, 3 Apr 2026). ### Independent characterisation On the evidence of FY2024–1H2026, Charm Engineering is best described as a financial holding shell with a residual equipment-service tail and an embryonic commodity-trading activity: 1. **Savings bank (dominant).** Charm Savings Bank takes deposits and makes loans in the Daegu–Gyeongbuk operating region. Customer deposits grew from KRW 531.3 bn (FY2024) to KRW 700.3 bn (FY2025), and FY2025 net income was KRW 5.4 bn. Revenue is interest and fee income (Dealsite, 2 Apr 2026; ETF Shopping). 2. **Display repair equipment (legacy, collapsing).** Capital equipment sold to panel makers was historically the core business. Customers included Chinese panel makers (CSOT, HKC, Visionox/"GVO" and BOE) and Korean panel makers. Non-financial revenue fell from KRW 18.3 bn (FY2024) to KRW 6.3 bn (FY2025) (Dealsite, 2 Apr 2026). The overseas parts-and-service activity in China and Vietnam is the main remaining recurring element. 3. **Scrap metal (new, unproven).** The company reports the scrap business on a net revenue basis, which suggests a brokerage or intermediation model. It has disclosed no capex plan, describing the business as in "pilot operation," and standalone PP&E is close to nil (Dealsite, 3 Apr 2026). **Revenue model mix (FY2025, derived):** about 89% financial-services income (savings bank), about 11% non-financial (equipment, parts and service, scrap). There is no subscription or licensing revenue. **Value-chain position:** a Tier-1 capital-equipment supplier to panel fabs (legacy) and a regional deposit-taking lender (current). **Customer types / end markets:** (i) display panel manufacturers in Korea, China and Vietnam (equipment); (ii) retail and SME borrowers and depositors in Daegu–Gyeongbuk (bank); (iii) scrap-metal buyers and sellers (new; counterparties not disclosed).

Revenue$0.0B
Employees26
Market CapN/A
Founded1973
Seongnam, South Korea
Changhae

Changhae Ethanol Co., Ltd.

Premium
Information Technology

Employee-count discrepancy: third-party databases list 55 (Simply Wall St) and 58 (Morningstar); the DART-based figure of 61 (FY2025) is used here. Changhae Ethanol is one of a small, licensed group of Korean producers of *jujeong* (주정) — fermented and refined ethyl alcohol that serves as the base spirit for diluted soju, Korea's mass-market liquor. Its Jeonju plant, expanded through the 2003 merger of Bohae Jujeong and the 2017 absorption of Jeolla Jujeong (ex-Hite Jinro Ethanol), makes it the volume leader in Korean fermented and refined spirit production by its own claim. Domestic spirit sales are channelled through a single sales agent, Korea Alcohol Sales (대한주정판매), in which producers' sales allocations track their shareholding; Changhae holds the largest stake (17.93%). Around this regulated, cash-generative core sit by-products (distillers' grains, CO2, condensed solubles), a plant-engineering subsidiary, waste-heat steam supply, tapioca trading from Vietnam, an early-stage bio-materials contract-manufacturing initiative, and a 21.7% equity stake in regional soju maker Bohae Brewery. The equity story is high yield, low valuation and slow volume decline. --- ### What the company does Changhae Ethanol converts starch- and sugar-based feedstocks — principally imported tapioca (cassava) chips, plus rice, barley and sugar-cane derivatives — into potable-grade ethanol. The company's main output is two grades of spirit: **Fermented spirit (발효주정):** ethanol produced by fermenting and distilling grain/tapioca mash. **Refined spirit (정제주정):** further purified alcohol produced by re-distilling crude or fermented spirit to the ~95% purity that soju makers dilute with water and sweeteners. According to its corporate website, in 2020 the company produced 26,078 kL of fermented spirit and 39,912 kL of refined spirit, figures it uses to support a claim of being first in the industry by production volume. ### Company's own description (paraphrased from website and business report) The company describes itself as a producer of high-quality spirit (fermented ethanol), spirit by-products and bio-materials, leveraging accumulated know-how and proprietary, self-designed automated process technology to lead the domestic spirit industry. It lists three business areas: (1) spirit, produced under HACCP-certified processes; (2) manufacture and sale of by-products — distillers' grains, carbon dioxide and condensed distillers' solubles (CDS); and (3) bio-materials as a diversification and future-value driver. DART-aggregated segment disclosure (Butler, Q2 2026) uses four reporting divisions: Spirits (주정사업부), Engineering (엔지니어링사업부), Energy (에너지사업부) and Trade (무역사업부). ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Overwhelmingly product sales (spirit and by-products); secondary project/service revenue (engineering, construction-equipment rental per Investing.com profile); steam sales (energy); commodity trading margin (tapioca, wood pellets, feed/compost inputs) | | Subscription / licensing | None identified | | Pricing mechanism | Spirit sold to Korea Alcohol Sales at prices set through the industry agent; increases have been infrequent (2008, 2012, Feb 2022 +7.8%, 2023 +9.8%) | | Volume mechanism | Each producer's sales volume is linked to its shareholding in Korea Alcohol Sales under the Liquor Tax Act framework (Etoday, 2016) | | Value-chain position | Mid-stream: imports feedstock (partly via own Vietnam trading subsidiary) → ferments/distils → sells spirit via monopoly agent → soju brewers (Hite Jinro, Lotte Chilsung, regional brewers including affiliate Bohae Brewery) | | Customer types | Single direct spirit customer (Korea Alcohol Sales); end-users are soju and other liquor makers; by-product buyers are feed, fertiliser and industrial-gas users; engineering clients are ethanol, environmental and energy plant owners | | End-markets | Korean diluted soju (dominant), industrial/other alcohol uses, animal feed, liquid fertiliser, industrial CO2, district/industrial steam, Southeast Asian commodity trade, biocontrol and bio-chemical CMO (nascent) | ### Independent characterisation Changhae is best understood as a regulated quasi-utility attached to a structurally shrinking end-market. The allocation system and the single sales agent remove most price competition and customer-acquisition cost, which explains durable operating margins of 12–15% in normal years and steady dividends. Against that, the business has almost no volume growth lever: domestic liquor shipments fell to 2.988M kL in 2025, the first sub-3M kL year since 1998 (National Tax Service data reported by Segye Ilbo, Aug 2026). Profit swings come mainly from (i) tapioca and energy costs versus the administered spirit price, (ii) the volatile, mostly loss-making subsidiaries, and (iii) below-the-line items tied to the Bohae Brewery stake. The 2026 transfer of the chairman's shares to his son settles succession and reduces governance uncertainty, but does not change the operating outlook.

Revenue$0.1B
Employees61
Market CapN/A
Founded1966
Jeonbuk State, South Korea
CGInvites

CG Invites Co., Ltd.

Premium
Information Technology

CG Invites is a small-cap KOSDAQ company in the middle of a deliberate transition. It is moving from first-generation Korean drug-discovery biotech (CrystalGenomics, the first company listed on KOSDAQ under the technology-evaluation special listing track in 2006) to a data-driven digital healthcare business. The transition is directed by its private-equity controlling shareholder, New Lake Alliance. The legacy asset base includes Acelex (polmacoxib), approved in 2015 as Korea's 22nd domestically developed new drug, and a clinical oncology pipeline anchored by ivaltinostat (CG-745, HDAC inhibitor, US Phase 2 in metastatic pancreatic cancer) and Korean rights to camrelizumab (PD-1). Since 2023, management has sold non-core holdings, cut R&D spending sharply, and consolidated externally sourced businesses. In FY2025 these were AI healthcare solutions, heating patches, automation equipment and genomic analysis, which together accounted for about 92% of revenue. The investment case now depends on whether the "Invites Loop" AI health platform generates revenue, including through a September 2026 China license. It also depends on resolving a US legal dispute with the founder over the ivaltinostat subsidiary, and on refinancing a negative working-capital position. --- ### Company's own description Third-party filings indexes summarize the company's self-description as follows. CG Invites is a biopharmaceutical company focused on digital genomics and personalized medicine, with four activity areas: 1. Genomics, using whole-genome sequencing. 2. mRNA-based personalized cancer vaccines. 3. Digital therapeutics (software-based interventions). 4. Chemical and biological drug development, covering oncology and inflammation (Acelex, ivaltinostat, camrelizumab). Management has described the change in direction more explicitly. A company official told Dealsite TV in May 2026 that since joining the Invites ecosystem in 2023, the company has been shifting toward digital healthcare. The official said the legacy pipeline cannot be wound down all at once, but the digital-healthcare direction has become concrete since 2025. ### Independent characterization On the evidence of FY2025 revenue composition, CG Invites is now best described as a diversified small-cap healthcare holding-type company. It has a residual drug-development pipeline and a nascent AI health-data platform. FY2025 consolidated revenue by product, as reported in the DART annual report and cited by Dailypharm on 8 May 2026: - AI healthcare solutions: KRW 8.2bn (30.7%) - Heating patches (hot packs): KRW 7.2bn (27.1%) - Automation equipment: KRW 4.7bn (17.5%) - Genomic analysis and other: KRW 4.6bn (17.4%) - Arthritis analgesic/anti-inflammatory (Acelex): KRW 1.7bn (6.3%) Prescription pharmaceuticals therefore contributed only about 6% of revenue. Standalone (parent-only) revenue in FY2025 was about KRW 11.8bn (Dealsite, 28 Sep 2026). This implies that roughly KRW 15.6bn, or about 57% of consolidated revenue, came from consolidated subsidiaries and businesses incorporated through acquisition or merger. Dealsite TV (May 2026) attributes the revenue growth to externally incorporated businesses and mergers rather than to in-house drug development. The specific entities that brought the heating-patch and automation-equipment businesses are not identified in the sources reviewed. ### Business and revenue model | Revenue stream | Model | Evidence | |---|---|---| | Acelex (polmacoxib 2mg) | Product sales (prescription drug, Korea), plus pursuit of export licensing (Russia in negotiation as of Jul 2025) | Dailypharm; Dealsite | | AI healthcare solutions / Invites Loop | Solution/service revenue in Korea, plus technology licensing abroad: China exclusive license with a 5% running royalty on net sales (Sep 2026); planned US licensing via a New Lake Singapore hub | Dailypharm; Dealsite | | Genomic analysis (NGS testing) | Testing-service fees. The service launched in April 2025 and received College of American Pathologists (CAP) accreditation in May 2025. | Financial News; Dailypharm | | Heating patches | Consumer/industrial product sales | Dailypharm (DART segment data) | | Automation equipment | Equipment sales | Dailypharm (DART segment data) | | Pipeline out-licensing | Upfront payments and milestones (historically CG-806 with Aptose, worth up to about KRW 487bn in total). Dealsite TV reports that technology-fee income has dried up. | Dailypharm; Dealsite TV | ### Value-chain position and customers **Pharmaceuticals:** originator and licensor. Acelex is sold to the Korean prescription market (hospitals and clinics). Clinical development is done through CROs and outsourced research, which was cut from KRW 3.6bn in 2024 to KRW 0.5bn in 2025 (Dailypharm). **Digital health:** platform/IP owner and licensor. The company acts as licensor through joint ventures (VISTA Invites Digital Ward Ltd, Hong Kong) and intends to keep IP-holder status for US expansion via New Lake Singapore (Dealsite, Jan 2026). **Customer types:** hospitals and health-screening institutions (for example, the KMI partnership of Jun 2026), corporate health programs and insurers (via VISTA in China), pharmaceutical licensees, and consumer and industrial buyers for heating patches and automation equipment. **End-markets:** Korean prescription NSAIDs, oncology (pancreatic cancer, NSCLC, hematologic cancers), precision genomics, AI preventive healthcare and chronic-disease management, China digital health, and consumer warming products.

Revenue$0.0B
Employees71
Market CapN/A
Founded2000
Seoul, South Korea
Central

Central Insight.Co., Ltd.

Premium
Information Technology

| Field | Detail | |---|---| | Current legal name | 주식회사 청호ICT / Chungho ICT Co., Ltd. | | Former names | Chungho Silup Co., Ltd. (청호실업, founding name, 1977); Chungho Computer (청호컴퓨터, name at the 1990 IPO per Seoul Shinmun, 24 May 1990); Chungho ComNet (청호컴넷); Central Insight Co., Ltd. (센트럴인사이트, 2020 to March 2023). Korean Wikipedia also lists Daecheong Electric (대청전기) as an intermediate name. | | Founded | 13 October 1977 (company website) | | Founder | Ji Dae-seop (지대섭), per Korean Wikipedia | | Incorporation jurisdiction | Republic of Korea | | Headquarters | 3F, 185 Hwanggeum 1-ro, Yangchon-eup, Gimpo-si, Gyeonggi-do, Korea (company website; Seoul Exchange) | | Seoul office | Gangnam branch, 31 Seolleung-ro 119-gil, Gangnam-gu, Seoul (company website) | | Legacy address still in data vendors | 15F SB Tower, 318 Dosan-daero, Gangnam-gu, Seoul (Morningstar profile; outdated) | | Exchange / ticker | KOSPI (Korea Exchange), A012600 / 012600.KS. Listed 10 July 1990; delisted 27 May 2025. | | Current trading venue | No exchange listing. Shares appear on the Seoul Exchange unlisted-share platform. Korean Wikipedia lists a K-OTC quotation under 012600. | | ISIN | KR7012600003 | | CUSIP | Not applicable (no US listing) | | Business registration no. | 208-81-07756 | | Shares outstanding | 46,634,517 common shares (KRX delisting notice, May 2025) | | Fiscal year end | 31 December | | Employees | Morningstar shows 40, with no date and apparently not consolidated. Korean Wikipedia shows 146 at 30 June 2015. The company says it runs 22 after-sales service branches, which implies a much larger consolidated workforce. A verified 3-year trend is not publicly disclosed in sources reviewed. | | Auditor | FY2020: Daesung Samkyung Accounting Corp. (issued a disclaimer of opinion; Edaily, March 2021). Current auditor not publicly disclosed in sources reviewed. | | Market capitalisation | No exchange market capitalisation since delisting. FY2025 consolidated book equity: KRW 49.7bn (NICE via Seoul Exchange). | | CEO | Cho Jung-hwan (조중환) (company website; Seoul Exchange) | | Controlling shareholder | J&AT Holdings (제이앤에이티홀딩스), a wholly owned subsidiary of private equity firm JC Partners, holding 27.14% (The Fact, 27 July 2024) | | Website | https://chunghoict.com (current); http://www.centralinsight.co.kr (legacy domain in source list) | | Main subsidiaries | Genexon Co., Ltd. (insurance software); Chungho Networks Co., Ltd. (nationwide after-sales maintenance); Innosure Co., Ltd. (insurance-agency hub platform; new business) | Chungho ICT is one of Korea's oldest makers of financial self-service equipment. It began supplying banking automation hardware in 1977. Before the 2010s it was a leading domestic supplier of cash dispensers (CDs) and automated teller machines (ATMs), with roughly 40% of the domestic CD market and 32% of the ATM market in 2008. A 2020 change of control, a speculative pivot under the Central Insight name, a 2021 audit disclaimer and alleged executive embezzlement led to a suspension of more than three years and, in 2025, delisting from KOSPI. Under JC Partners since 2023, the company has returned to its core business: ATMs, utility-bill payment kiosks and a nationwide maintenance network. Around that core it has built smaller lines in attendance terminals and kiosks, semiconductor ROM-writing contract manufacturing, and insurance software. It is a small, domestically focused company in a market where Korea's bank ATM fleet shrinks every year, and its equity is now unlisted. --- ### What the company does Chungho ICT designs, manufactures, sells and maintains automation equipment for financial institutions. Its website sets out four business areas: 1. **Financial business:** ATMs, utility-bill payment machines, information readers, passbook printers and tablets for banks, plus related software development and maintenance. 2. **Attendance terminals:** time-and-attendance terminals, which the company says it is supplying more widely for construction workers. 3. **Kiosks:** general self-service kiosks. 4. **Semiconductor OEM:** made-to-order production of ROM-written semiconductor products. The company's self-description, paraphrased from its website, has three parts: - It has worked in financial-sector automation since 1977. It supplies automation equipment and also manages its operation, and services scanners and network equipment. - It is widening its scope from hardware, software and maintenance into systems integration (SI). The 2024 acquisition of insurance-software developer Genexon is meant to make it an integrated IT solutions provider covering hardware, software and maintenance across banking and insurance. - It uses its manufacturing and R&D capabilities to enter new businesses, namely attendance terminals and semiconductor OEM. It runs a customer service centre and 22 after-sales branches nationwide. ### Business model and revenue model Revenue comes from four sources: **Equipment sales:** ATMs, bill-payment kiosks and other terminals, sold mainly through competitive bank tenders and sometimes through intermediaries. One example is a KRW 827.64m utility-bill payment machine order placed via IBK System for Industrial Bank of Korea (Asia Economy, 24 December 2024). **Multi-year maintenance and outsourced fleet management:** for example, a KRW 8.3bn maintenance contract with NH Nonghyup Bank running from 1 January 2023 to 31 July 2024 (company news, citing Daily Economy, 30 March 2023). The company also cites "total outsourcing" fleet management supported by its FEMS monitoring system. **Contract manufacturing:** semiconductor ROM writing. **Software and services:** insurance-sector software through Genexon and a planned insurance-agency hub platform through Innosure. A product, service and subscription split is not publicly disclosed in sources reviewed. Based on the business description, the model is best described as hardware sales plus a recurring service annuity. In bank ATM markets, maintenance revenue is typically steadier and higher-margin than box sales. This is an analyst characterisation, not company disclosure. ### Value chain position Chungho ICT is an original equipment manufacturer (OEM) and service provider. Its core value chain position is: **Design and assembly:** of ATMs and kiosks. Its global ATM line (ComNet 7402rb) is built to international standards with multi-language capability. **Proprietary middleware and industrial software tools:** The website mentions in-house development tools. **Installed-base service:** through 22 regional branches and a monitoring and control system (FEMS). How much of the core cash-handling modules it makes itself versus buys in is not publicly disclosed. Its 2018 joint venture with Fujitsu Frontech covered development of cash-handling and settlement products, which suggests partner sourcing of some modules (Fujitsu Frontech press release, 26 April 2018). ### Customer types and end-markets **Banks:** NH Nonghyup Bank, local NH/livestock cooperatives, Industrial Bank of Korea, Kwangju Bank, Jeonbuk Bank, Daegu Bank, Busan Bank, Suhyup Bank (maintenance), KB Kookmin Bank, Woori Bank and Shinhan Bank (historic). **Mutual finance:** Korean Federation of Community Credit Cooperatives (MG Saemaul Geumgo) and National Credit Union Federation (Shinhyup). **Postal finance:** Korea Post Information Center (ATM supply contract, 2016). **Construction:** attendance terminals for construction workers. **Semiconductor and automotive electronics:** ROM-writing OEM, including a 2024 automotive semiconductor supply contract. **Insurers and insurance agencies:** through Genexon and Innosure. **Export customers (historic):** Iran (ATM and management system contract, 2013), South Africa (cash dispenser exports under the Central Insight name), and subsidiaries set up in 2001 in the US, Canada and China. ### Independent characterisation Chungho ICT is a sub-scale incumbent in a structurally declining domestic hardware market. Its strengths are a long installed base, entrenched relationships with state-linked and regional banks, and a dense service network. It has tried several times to diversify (bio, cosmetics, digital assets in 2020–21; kiosks, semiconductors and insurance software since 2023). Only the post-2023 initiatives show measurable revenue. Consolidated revenue rose from KRW 21.4bn in FY2023 to KRW 35.5bn in FY2025, but by FY2025 more than a quarter of it came from subsidiaries (derived from consolidated versus separate data). Profitability is thin: the consolidated operating margin moved from 8.2% in FY2024 to -1.1% in FY2025.

Revenue$0.0B
Employees40
Market CapN/A
Founded1977
Gimpo, South Korea
CentralBio

Central Bio Co., Ltd.

Premium
Information Technology

Joongang Advanced Materials is a loss-making KOSDAQ micro-cap. It has two legacy operating businesses: telecommunications equipment, which made up 84% of Q2 2026 revenue, and PVC building materials and windows (16%). On top of these sit several strategic adjacencies, most of them still pre-revenue. Since 2023, the company's equity story has rested mainly on lithium hexafluorophosphate (LiPF6), a key electrolyte salt for lithium-ion batteries. It has pursued LiPF6 through a 50% joint venture, EDL, with Enchem, a Korean electrolyte maker, and through LiPF6 trading. The company sits inside a cross-shareholding group controlled by Enchem CEO Oh Jung-kang through Enchem and Kwangmu. Since 2025 it has also moved into defense and security, as the exclusive Korean value-added reseller for UK radar maker Blighter Surveillance Systems. Revenue (~KRW 20 bn) is small relative to its market value. The investment case therefore depends on executing these new businesses, on group governance, and on financing, not on current earnings. --- ### Company self-description Korean press descriptions drawn from company statements say that the company was founded in April 1999 and listed on KOSDAQ in 2001. At that time it operated telecommunications equipment, PVC products and building-materials manufacturing, and household goods distribution. In 2017 it absorbed affiliate Joongang Living Sash (중앙리빙샤시), which added PVC window-frame (sash) manufacturing (Asia Economy, January and October 2021). StockHub's summary of the company's business-report disclosures lists these activities: communication equipment and video/information display devices, PVC building materials, window and interior products, LED and lighting, distribution, and secondary-battery materials (StockHub, 2026). From 2023, company communications repositioned the business around secondary-battery materials, specifically LiPF6 trading and production. The August 2023 rename to "Advanced Materials" was disclosed as reflecting business expansion centred on secondary batteries and an improved corporate image (Asia Economy, 12 September 2023). In 2026 the company presented itself in press materials as an advanced defense and security solutions company, centred on Blighter e-scan radars (Money Today, 2 September 2026). ### Independent characterization Taken together, the disclosures describe a holding-style micro-cap with a small legacy industrial base. Several themed initiatives have been layered onto that base over time: - construction and civil engineering (2021) - smart farms and real estate development (2021) - lithium salt (2023 onward) - information security via Initech (2025, reversed within two months) - rail/hydrogen tram (2025) - radar and anti-drone defense (2025–2026) Few of these initiatives show up in reported revenue. The Q2 2026 revenue mix still consists entirely of the two legacy segments: telecommunications (84%) and PVC/building materials (16%) (Butler.works, Q2 2026). ### Business model and revenue model | Dimension | Characterization | Basis | |---|---|---| | Revenue model | Product sales (telecom equipment, PVC windows/building materials); trading/distribution margin (LiPF6 resale to Enchem, 2023–2024); equity-method exposure to EDL JV | Segment disclosure (Butler.works); LiPF6 contracts (Asia Economy, Aug–Nov 2023) | | Service / subscription / licensing | No material service, subscription, or licensing revenue disclosed. Radar business includes local technical support and MRO, but revenue not disclosed | Money Today (Sep 2026) | | Value chain position | Telecom: equipment manufacturer. PVC: manufacturer of window/building products. LiPF6: distributor today, prospective upstream producer via EDL. Radar: reseller/integrator (VAR) of imported hardware | Multiple | | Customer types | B2B and B2G. Enchem was the disclosed LiPF6 counterparty. Defense, critical infrastructure, and public safety targeted for radar | Asia Economy (2023); Hankyung Money (Mar 2026) | | End-markets | Telecommunications infrastructure; residential and commercial construction; lithium-ion battery electrolyte supply chain (US/EU via Enchem); defense and homeland security; urban rail (Daejeon Line 2 hydrogen tram) | Multiple |

Revenue$0.0B
Employees108
Market CapN/A
Founded1999
Anyang, South Korea
CENOTEC

CENOTEC Co., Ltd.

Premium
Information Technology

CENOTEC is a small-cap Korean advanced-ceramics manufacturer whose core franchise is ceramic grinding and dispersion beads (zirconia-, alumina- and zircon-based media) used in ultra-fine milling for mineral processing, paper/ink/paint, calcium carbonate, MLCC electronic materials and battery-materials production. The company states it was the first in Korea to mass-produce ceramic beads and describes itself as the country's only ceramic bead producer. It also sells zircon flour and zirconium silicate powders (precision casting, tiles), welding flux, and catalyst carriers. Since 2024–2026 it has been pivoting part of its asset base toward cathode additives for lithium-ion batteries, notably cobalt hydroxide, with first mass-production shipments in February 2026 and a strategic MOU with Umicore. Controlled since 2017 by E&F Private Equity, the company returned to profitability in FY2025 after three loss-making years, but remains highly leveraged relative to its earnings base, export-dependent (≈65% of FY2025 sales), and exposed to mining and battery-cycle demand. --- ### What the company does CENOTEC manufactures engineered ceramic materials in four broad product families: 1. **Ceramic beads (grinding/dispersion media)** — spherical ceramic media in a range of specific gravities (SG 3.2 to SG 6.0) used inside stirred mills, bead mills and horizontal mills to grind or disperse other materials to micron or sub-micron particle sizes. End uses include ultra-fine grinding of mineral ores (iron ore, copper, gold, silver), calcium carbonate, paper coating pigments, inks and paints, and electronic materials such as MLCC (multilayer ceramic capacitor) powders and battery cathode/anode precursors. 2. **Ceramic powders** — zircon flour (Cenoflour) for foundry coatings, precision investment casting and refractories; zirconium silicate powder (Cenosilicate) for tile and sanitaryware glazes. 3. **Ceramic flux** — high-functionality welding flux (Cenoflux), historically linked to shipbuilding welding applications. 4. **Secondary battery materials and catalyst carriers** — nano-milled additive powders for lithium-ion cathode materials (zirconia ZrO₂, cobalt(II) hydroxide Co(OH)₂, alumina Al₂O₃, cobalt(II,III) oxide Co₃O₄) and ceramic catalyst carriers ("Globular Carrier") for petrochemical and hydrogen-industry catalysts. The company's website states that it works with more than 200 customers and partners worldwide across mining, electrical/electronics, paper and tile industries (Company website, accessed October 2026). ### The company's own description (paraphrased) The company's investor-facing summary (as reproduced by ValueLine, 26.2Q update) characterizes CENOTEC as a 1999-founded firm that achieved Korea's first commercial mass-production of ceramic beads and remains the country's only ceramic bead producer. It describes four business divisions — grinding/dispersion ceramic beads, ceramic powder, ceramic carriers, and secondary battery additives — serving MLCC and battery materials manufacturing, mining, paper/ink/paint, shipbuilding welding, hydrogen and petrochemicals. It notes import substitution after building its first production line in 2000, overseas market development from 2002, the launch of a cathode additive business in 2024 with full supply from Q1 2025, and a goal of becoming a high-value composite materials specialist by 2030, with next-generation ultra-small MLCC beads, catalyst carriers and battery additives as priority growth areas. ### Business model and revenue model | Dimension | Characterization | Basis | |---|---|---| | Revenue model | ~100% product sales (manufactured materials). No disclosed service, subscription or licensing revenue | Segment data (S&P Global/StockAnalysis); company product pages | | Pricing | Per-tonne / per-kilogram material sales under purchase orders and periodic supply contracts; some multi-month contracts disclosed (e.g., KRW 4.6 B battery additive contract running May–Dec 2026) | Finance Scope (14 May 2026) | | Value chain position | Mid-stream specialty materials processor: buys zircon sand, zirconia, alumina, yttria, ceria and cobalt intermediates; converts them via fusion/sintering, spheroidization and nano-milling into consumable media and functional powders | Company website; Dealsite (March 2025) noting heavy China sourcing of alumina and zirconia | | Customer types | Mining companies and mining-consumables distributors (South Africa, Australia, South America); paper/pigment and paint/ink producers (Americas, Europe); MLCC makers (Samsung Electro-Mechanics registered as first-tier vendor in 2020); cathode material producers (Korea and overseas); welding consumable makers; catalyst producers | Company history; Finance Scope; Daum (March 2025) | | Consumable nature | Beads wear down in use and must be replenished; demand tracks mill throughput at customer sites rather than customer capex alone | Industry characteristic; Finance Scope (May 2026) attributes bead demand growth to LFP line investment, MLCC output and mining activity | ### End-markets served | End-market | Products | Demand driver (as reported) | |---|---|---| | Mining (ultra-fine grinding) | CAS32, CPA37, CAS37, CAZ40, CZA45/50, CZC60 beads | Metal prices and concentrator throughput; Q1 2026 PR cited higher copper and gold prices | | Paper, CaCO₃, paint, ink | CZS40, CZA45/50, CZC60, CZY60 beads | Pigment and coating production in Americas/Europe | | Electronics (MLCC) | CSS36 and small-diameter CZY beads | Automotive-electronics-driven MLCC output | | Battery materials processing | Small beads for precursor/cathode milling; LFP line media | Korean LFP supply-chain build-out (Q1 2026 PR) | | Battery cathode additives | ZrO₂, Co(OH)₂, Al₂O₃, Co₃O₄ powders | NCM cathode production; supply-chain diversification away from China | | Foundry / precision casting / refractories | Cenoflour | Casting volumes | | Ceramics (tile, sanitaryware) | Cenosilicate | Construction-related ceramics demand | | Welding (shipbuilding) | Cenoflux | Shipbuilding activity | | Catalysts (petrochemical, hydrogen) | Globular catalyst carriers | Catalyst replacement cycles | | Aerospace/defense | Cooperation framework established 2025 (no revenue disclosed) | Company history | ### Independent characterization CENOTEC is best understood as a niche, export-oriented consumable-media manufacturer with a legacy mining exposure that the controlling private equity owner has deliberately diluted in favour of electronics and battery-related applications. Its competitive position rests on in-house fusion and nano-milling know-how and a broad SG range, which lets it serve both low-cost mining media and high-density yttria-stabilized zirconia media for electronics. The economic profile is that of a capital-intensive, working-capital-heavy processor: inventories have historically equalled 8–12 months of cost of sales, debt has exceeded equity in every year from FY2021 to FY2025, and interest expense has absorbed most of operating profit. The FY2025–H1 2026 earnings recovery is real (TTM operating margin 9.8%), but the investment case now hinges on whether the cobalt hydroxide/cathode additive business can scale to the stated ~20% of revenue in 2026 without a dilutive financing.

Revenue$0.0B
Employees102
Market CapN/A
Founded1999
Haman-gun, South Korea
Cenit

Cenit Co., Ltd

Premium
Information Technology

Cenit is a small-cap Korean industrial holding company built around a niche stainless-steel cold-rolling mill in Uiryeong, South Gyeongsang Province. The mill produces thin and ultra-thin precision stainless strip and coil (BA, 2B and 2D finishes, plus high-hardness grades) for appliances, automotive, construction, electronics and industrial users in Korea, Europe, North America, Japan and other export markets. Over two decades the controlling shareholder has layered unrelated cash-generating and real-asset businesses on top of the steel base: - cinema property ownership and operation - ready-mix concrete and aggregates (Yeongsan Concrete Industrial; Dongbu C&C) - pharmaceutical testing services (Pharmaentech) - steel trading (Hyundai SNT) - stainless pipe operations in Dalian, China Its newest bet is Innogreen Metal, a Dangjin-based recycler that recovers vanadium, molybdenum and nickel from refinery spent catalysts and began commercial production in July 2026. Consolidated revenue is roughly KRW 127–131 bn. Margins are thin, the balance sheet is leveraged, and the stock trades below book value. --- ### What the company does | Subsidiary | Business | Stake (FY2025 report) | |---|---|---| | Yeongsan Concrete Industrial Co., Ltd. (영산콘크리트공업) — major subsidiary | Ready-mix concrete manufacturing and sales | 86% | | Dongbu C&C Co., Ltd. ((주)동부씨앤씨) | Aggregate production and sales | 100% (acquired July 2024) | | Pharmaentech Co., Ltd. ((주)파마엔텍) | MFDS-designated testing of pharmaceuticals and quasi-drugs | 87.41% | | Hyundai SNT Co., Ltd. ((주)현대에스엔티) | Steel sales/trading, Busan | 87.76% | | Innogreen Metal Co., Ltd. ((주)이노그린메탈) | Spent-catalyst recycling and rare/minor-metal recovery, Dangjin | 59.46% | | Two Dalian stainless pipe companies (대련특래미불수강관유한공사; 대련특미불수강관유한공사) | Stainless steel pipe | Not disclosed in accessible sources | Cenit's revenue comes from three layers. **Layer 1: Parent-level steel business ("Steel Division").** The parent buys hot-rolled stainless coil, mainly 300-series austenitic and 400-series ferritic grades, and re-rolls it at its single Uiryeong cold-rolling mill into thin and precision-gauge cold-rolled stainless strip and coil. - Finishes are BA (bright annealed), 2B (annealed, pickled and skin-passed) and 2D (annealed and pickled). - Separately, the company lists "high-hardness sheet" (고경도판) among its main products. - The division also resells purchased stainless products ("merchandise"). This line grew 78.5% year on year in H1 2026, to KRW 7.23 bn (Steel & Metal News, Aug 2026, citing the H1 2026 report). **Layer 2: Parent-level non-steel businesses.** **Cinema operation:** the company owns cinema properties and operates them under consignment arrangements with national chains. **Real-estate leasing:** at least one cinema building has been leased to CGV for rental income (etoday, Aug 2014). **Layer 3: Consolidated subsidiaries.** Seven consolidated subsidiaries at end-2024, three of them "major" (FY2024 Annual Report): Sources: ETF Shopping (FY2025 Annual Report investee table); Steel & Metal News (Feb 2025). ### Company's own description The FY2025 annual report, as summarised by Steel & Metal News (27 March 2026), describes the business this way: - The steel division competes by moving away from commodity (general-purpose) products toward specialised precision thin-gauge rolled products. - Main customers are automotive, home appliances and construction in the domestic market, plus exports to Europe, North America and Japan. - Alongside steel, the company operates ready-mix concrete, cinema, pharmaceutical testing and waste-resource recycling. - Management named two priorities: (i) secure stable raw-material supply for the recycling business while raising recovery rates and purity, and enter new markets; (ii) restore profitability in the legacy businesses through new products, cost reduction and productivity gains. ### Revenue model | Revenue stream | Model | Notes | |---|---|---| | Cold-rolled stainless (own production) | Product sales; spot and contract pricing per tonne; pass-through of nickel and hot-rolled coil costs with lag | H1 2026 average domestic price KRW 5.82 mn/t; export price KRW 4.763 mn/t | | Stainless merchandise | Buy-and-resell trading margin | Fast-growing in 2026 | | Ready-mix concrete and aggregates | Product sales to construction sites; regional, freight-constrained | Sensitive to construction starts, cement and freight costs | | Cinema | Box office and concessions under consignment operation; rental income where leased | Small share of revenue | | Real-estate leasing | Rent | About 0.1% of revenue (stockstalker, c. 2022 breakdown) | | Pharmaceutical testing | Fee-for-service testing (MFDS-designated) | Small | | Spent-catalyst recycling | Gate fees for waste treatment plus sale of recovered V, Mo, Ni and alumina-based materials | Commercial production since July 2026 | There is no subscription or licensing revenue. Revenue is overwhelmingly product-based, with a small services tail. ### Value-chain position and customers In stainless steel, Cenit is a downstream re-roller ("cold-rolling single-stand / re-rolling mill", 냉연 단압밀). It buys hot-rolled coil from integrated producers or importers and adds value through thickness reduction, annealing, finishing and slitting. It has no melting capacity and no control over nickel or ferrochrome input costs. Its customers are: - OEM and parts makers in appliances, automotive, construction and electronics - stainless distributors and service centres; distributor sales were KRW 9.65 bn in H1 2024, up 12% (Steel & Metal News, Aug 2024) - export buyers in Europe, North America, the Middle East, Oceania, Japan and other Asian markets In concrete and aggregates, it is a regional materials supplier to construction contractors. In cinema, it is an asset owner and consignment operator. In recycling, it sits between refineries (generators of spent hydro-processing catalyst) and metal consumers (steel, alloy and chemicals industries). ### Independent characterisation Cenit is best understood as a founder-controlled micro-conglomerate rather than a pure-play steel company. - The steel division supplied roughly half of consolidated revenue in 2025–26: KRW 63.8 bn of KRW 127.0 bn in FY2025, and 54.3% in H1 2026. Its volumes are small, with H1 2026 production of 8,929 t. - Its profitability is set by the spread between the domestic selling price and 300-series hot-rolled coil cost. In H1 2026 that spread compressed: input cost rose KRW 357k/t while the domestic price rose KRW 325k/t. - The concrete subsidiary is the largest non-steel asset (total assets KRW 105.7 bn) but is cyclical and suffered a 2025 profitability decline. - Capital allocation since 2023 has tilted toward Innogreen Metal. Group capex jumped to KRW 32.7 bn in FY2025 and net debt rose to KRW 54.2 bn. The investment case therefore rests on the success of the recycling venture and a recovery in construction and stainless demand, more than on the legacy rolling mill.

Revenue$0.1B
Employees391
Market CapN/A
Founded1995
Uiryeong-gun, South Korea
Cenergy

Cenergy Holdings SA

Premium
Information Technology

Cenergy Holdings is a Brussels-domiciled, Greece-operated industrial holding company. It owns two energy-infrastructure manufacturers: Hellenic Cables (power, telecom and submarine cables, including turnkey EPCI interconnections) and Corinth Pipeworks (large-diameter steel line pipe for gas, carbon capture and hydrogen networks). Controlled by Viohalco and listed in Brussels and Athens, the group has transformed since 2021. It has moved from a low-margin, metal-price-driven fabricator into a project-led supplier for grid interconnection, offshore wind and energy security. Revenue grew from EUR 1.05bn in FY2021 to EUR 2.06bn in FY2025, and a-EBITDA more than tripled to EUR 348m. Its competitive identity is that of a fast-scaling "challenger" to Prysmian, Nexans and NKT in subsea and high-voltage cables, now qualified up to 525 kV HVDC. It is also a technically differentiated, Tier-1 line-pipe supplier. A record backlog of about EUR 3.9bn at June 2026, plus a EUR 1.5bn HVDC award in August 2026, underpins visibility to 2030. Expansion into the US (Maryland) and UK (Hartlepool) is the next leg. --- ### Company's own description The company describes itself in its FY2025 and H1 2026 releases as a Belgian holding company listed on Euronext Brussels and Euronext Athens. It invests in leading industrial companies focused on growing global demand for energy transfer, renewables and data transmission. Its portfolio consists of two companies: - **Hellenic Cables**, characterised as one of Europe's largest cable manufacturers, producing power, telecom and submarine cables. - **Corinth Pipeworks**, characterised as a global leader in steel pipes for the energy sector and a major producer of steel hollow sections for construction. ### Independent characterisation Cenergy is best understood as two distinct industrial franchises sharing a holding-company balance sheet, a controlling shareholder and a single CEO. **Cables (71% of FY2025 revenue; 69% of FY2025 a-EBITDA).** This segment has two business units: 1. **Projects.** Turnkey or supply-only submarine and onshore high-voltage cable systems for transmission system operators (TSOs), offshore wind developers and installation contractors. Contracts are long-dated, milestone-billed and recognised over time, which shows up as contract assets and liabilities on the balance sheet. Projects revenue rose 38% in FY2025 as the expanded Corinth subsea plant ramped up. 2. **Products.** Medium- and low-voltage power cables, telecom and data cables, and special-purpose cables, sold through utility frame contracts, distributors and industrial customers. This is a volume business that is sensitive to copper and aluminium pass-through and to construction and distribution-grid capex. Products revenue grew about 14% in FY2025 and about 20% in H1 2026. **Steel Pipes (29% of FY2025 revenue; 31% of FY2025 a-EBITDA).** This segment manufactures welded line pipe at Thisvi, Greece: longitudinal submerged-arc welded (LSAW) and high-frequency welded (HFW) pipe, with external and internal coating and, since 2025, concrete weight coating. It also produces hollow structural sections. The business is project-based, bidding into onshore and offshore gas pipelines, carbon-capture-and-storage (CCS) lines and hydrogen-ready networks worldwide. It has no commodity hedging available for steel, so margins depend on bid discipline and project mix. The 2026 acquisition of the Hartlepool (UK) LSAW mill is intended to double LSAW capacity. ### Revenue model mix | Revenue type | Character | Approx. share | Basis | |---|---|---|---| | Cable projects (EPCI and supply) | Over-time, milestone-based contract revenue | ~40% of group (derived) | FY2025 projects revenue ≈ EUR 790m. Derived from FY2024 projects ≈ EUR 573m plus EUR 217m growth. | | Cable products | Point-in-time product sales; frame contracts | ~31% of group (derived) | Cables revenue EUR 1,464m less projects ≈ EUR 790m | | Steel pipe projects | Contract/product sales per project | ~29% of group | Segment revenue EUR 597m (FY2025) | | Services, licensing, subscriptions | Installation coordination, testing, spares, repair support | Not separately disclosed | Bundled within project contracts | ### Value-chain position **Upstream:** Cenergy buys copper and aluminium rod or cathode (much via Viohalco-related channels), XLPE compounds and steel plate and coil from third-party mills. It is not vertically integrated into steelmaking. **Midstream (core):** Conductor drawing, insulation extrusion, armouring, high-voltage testing, pipe forming, welding and coating. **Downstream:** Turnkey integration and installation through partners: DEME Offshore, Jan De Nul, Asso.subsea and Seaway7 appear as consortium partners or customers in disclosed awards. ### Customer types and end-markets | End-market | Example customers / projects disclosed (FY2023–H1 2026) | |---|---| | Transmission interconnectors | IPTO/ADMIE (Greece), 50Hertz (Germany), TenneT (Germany), RTE (France), Elia (Princess Elisabeth Zone, Belgium), Sweden–Denmark 400 kV link | | Offshore wind (export and inter-array) | Ørsted (Hornsea 3, South Fork, Revolution), RWE (Thor, North Sea sites), Vattenfall (Norfolk), Ocean Winds (BC-Wind), Equinor/Polenergia (Baltyk II/III), PGE/Ørsted (Baltica 2), East Anglia 2/3, Dieppe Le Tréport | | Onshore T&D grids | European TSO and DSO frame contracts for LV/MV/HV; IPTO undergrounding (Evia, Messatida) | | Gas transmission | DESFA, Snam (Adriatica), Gasunie (framework), OMV Petrom (Neptun Deep), Chevron (Tamar, Leviathan), NOMAGAS | | CCS / hydrogen | ENI HyNet (UK), Porthos (Netherlands), ONE-Dyas N05-A (100% hydrogen-certified), DESFA hydrogen-ready lines | | US offshore and inland energy | Trion deepwater (Gulf of Mexico), US inland gas and CCS pipe; Silver Run Expansion 230 kV submarine cable (US) | | Telecom / data | Telecom and data cables (products business); data-centre-driven power demand cited in the H1 2026 outlook |

Revenue$2.3B
Employees4,192
Market CapN/A
Founded2016
Brussels, Belgium
Celyad

Celyad Oncology SA

Premium
Information Technology

Celyad Oncology is a Belgian former clinical-stage CAR-T cell therapy developer that has been reduced, through a series of restructurings between 2022 and 2026, to an intellectual-property holding and licensing shell. It pioneered NKG2D-receptor-based CAR-T cells (licensed from Dartmouth College via Celdara Medical) and non-gene-edited allogeneic approaches using T-cell receptor inhibitory molecules and short-hairpin RNA (shRNA), but discontinued clinical development in late 2022 and all R&D in August 2025. It sold its research facility (EUR 3M, 2025) and its legacy C-CATHez cardiac catheter to CellProthera (up to EUR 5M deferred plus royalties, February 2026). With roughly four employees, a treasury position of EUR 0.1M at 30 June 2026 topped up by a EUR 0.5M Fortress placement, and a market value near EUR 8M, Celyad's equity value now rests on monetising its CAR-T patent estate through out-licensing — under the effective control of Fortress Investment Group. --- ### Company self-description In its current boilerplate, Celyad describes itself as a biotechnology company focused primarily on unlocking the potential of its intellectual property, headquartered in Mont-Saint-Guibert (FY2025 release, 2 Apr 2026). The 2025 business highlights state that it remains focused on partnering its IP and has progressed discussions with potential partners for selected out-licensing of its technologies. ### Independent characterisation Celyad is no longer an operating biotech. It is a listed IP vehicle whose assets are (i) a CAR-T patent portfolio — NKG2D-based CARs, allogeneic platforms (TIM and shRNA), and related know-how — and (ii) contingent consideration from the C-CATHez sale. It has no product revenue, no clinical programmes, no laboratory, and a skeletal staff. Its cost base has been cut from ≈ EUR 30M per year (2021–2022 R&D plus G&A) to an H1 2026 operating loss of EUR 1.2M. Its survival depends on small, repeated equity injections from Fortress, which controls the company. Value realisation would come from: licence fees/milestones/royalties from third parties using its patents; milestone payments from CellProthera; or a corporate transaction (reverse merger/shell sale) leveraging the listing. ### Revenue model | Revenue type | FY2025 | Comment | |---|---|---| | Product sales | ≈0 | Residual EUR 21k revenue in FY2025 (cost of sales EUR 8k) — likely legacy catheter or service items | | Licensing / royalties | 0 recognised | Target business model; no firm licence signed as of FY2025 (no change in fair value of Dartmouth/Celdara contingent liabilities) | | Asset-sale consideration | Recognised in other income | Research-facility sale gain EUR 2.3M (2025); C-Cath gain (H1 2026) | | Grants / R&D tax credits | Recognised in other income | Walloon Region grant income and R&D tax-credit derecognition gains (2025) | ### Value-chain position and customers Upstream IP originator/licensor in cell therapy. Prospective counterparties are CAR-T and cell-therapy developers (pharma and biotech) that may need freedom-to-operate under Celyad's NKG2D or allogeneic patents, plus CellProthera for the catheter. End-markets: oncology cell therapy (haematological and solid tumours) and, via the catheter, cardiac regenerative medicine.

RevenueN/A
Employees4
Market CapN/A
Founded2004
Mont-Saint-Guibert, Belgium
Celltrion

Celltrion Pharm, Inc.

Premium
Information Technology

Celltrion Pharm is the Korean commercial and fill-finish arm of the Celltrion biosimilar group. It runs three businesses: **Chemical pharmaceuticals:** A domestic prescription franchise anchored by the liver drug Godex, the hypertension drug Dilatrend, and diabetes and hypertension brands acquired from Takeda in 2020 (Nesina, Actos, Idalbi). **Biosimilars:** Exclusive domestic sales of parent Celltrion's biosimilars, from legacy Remsima, Truxima and Herzuma to newer Yuflyma, Vegzelma, Steqeyma, Omlyclo, Eydenzelt, Stoboclo-Osenvelt and Avtozma. **Contract manufacturing (CMO):** Mainly prefilled-syringe (PFS) fill-finish for Celltrion's subcutaneous products sold globally, including Remsima SC (US brand Zymfentra) and Yuflyma, from GMP-certified lines in Cheongju. FY2025 revenue reached a record KRW 536.4 bn, with operating profit of KRW 56.1 bn. The company's growth and margins are increasingly driven by Celltrion-linked biosimilar distribution and CMO volumes rather than generics. That shift makes it a leveraged, but concentrated, play on its parent's subcutaneous-formulation strategy. --- **What the company does.** Celltrion Pharm develops, manufactures and sells chemical (small-molecule) medicines in Korea. It is the exclusive Korean distributor of Celltrion, Inc.'s biosimilars. It also provides contract manufacturing services, principally aseptic filling of prefilled syringes. Third-party company descriptions (e.g., the StockHub profile derived from exchange data) list its therapeutic coverage as: - liver function improvers - anti-inflammatories and antihistamines - respiratory, cardiovascular and gastrointestinal drugs - hormone and metabolic-disease drugs - antibiotics and antifungals - nutritional and tonic products - immunology and oncology biologics Customers are university and general hospitals, clinics, and community pharmacies. **Revenue model.** Revenue is overwhelmingly product sales plus contract manufacturing service fees. There is no material subscription or licensing income. Based on FY2025 disclosed segment data: **Chemical products:** (owned brands, in-licensed and acquired brands, generics): ~40% of revenue on the disclosed segment figure. The share is higher if undisclosed "other" revenue is chemical. **Biosimilar distribution:** ~24%. Celltrion Pharm buys finished biosimilars from Celltrion and resells them in Korea. This is a distribution-margin model. **CMO / contract services:** ~26%. Mostly PFS commercial production for Celltrion, plus commercial production of in-sourced products and other pharmaceutical services. In H1 2026, biosimilar plus CMO revenue exceeded 53.8% of sales for the first time (IBK Investment & Securities initiation, September 2026). That marks the structural pivot away from generics. **Value-chain position.** **Chemicals:** vertically integrated. R&D of incremental modified drugs (개량신약) and combinations, API sourcing, finished-dose manufacturing at Ochang and Jincheon, and domestic sales and marketing. The company has "in-sourced" production of Takeda-origin brands (Nesina, Actos, Idalbi) that were previously imported, improving gross margin. **Biosimilars:** downstream only. Domestic commercialisation (hospital drug-committee listings, tenders, medical marketing) of products developed and manufactured by Celltrion. **CMO:** mid-stream. Drug product (fill-finish) manufacturing of Celltrion drug substance into prefilled syringes for global supply. **Customer types and end markets.** - Korean tertiary and general hospitals (biosimilars, specialty chemicals) - Clinics and pharmacies (primary-care chemicals) - Celltrion, Inc. as a related-party CMO customer. IBK estimated ~88% of H1 2026 CMO revenue came from Celltrion-directed PFS production. End markets: Korean prescription drug market (hepatology, cardiometabolic, diabetes, immunology, oncology, ophthalmology, allergy/respiratory, bone), plus global SC biologic demand indirectly via CMO. **Company's own characterisation.** In its earnings releases the company describes FY2025 as a year in which top-line growth combined with cost and cost-of-goods improvements. It names three operating levers: 1. strengthening competitiveness of core products; 2. keeping PFS fill-finish lines at maximum utilisation; 3. improving chemical profitability through in-sourced brands (Nesina, Actos, Idalbi). It frames 2026 as continued "high growth" with a profitability focus. (Paraphrased from the FY2025 preliminary results release, 5 February 2026.) **Independent characterisation.** Celltrion Pharm is best understood as a captive service and distribution satellite of Celltrion, Inc., with a declining-share generics base attached. Its economics are set by three things: - domestic biosimilar uptake, which Korean government policy increasingly favours; - Celltrion's global SC-formulation volumes, which drive PFS utilisation; - intra-group transfer pricing on both the distribution and CMO legs. This creates genuine growth optionality, notably the announced KRW 2 trn PFS capacity plan. It also creates material related-party concentration and governance considerations. Those considerations were central to the failed 2024 merger, when parent-company shareholders argued Celltrion Pharm's market value exceeded its fundamental value.

Revenue$0.4B
Employees992
Market CapN/A
Founded1976
Cheongju, South Korea
Celltrion

Celltrion, Inc.

Premium
Information Technology

Celltrion is South Korea's largest independent biosimilar company and one of the three or four most consequential biosimilar franchises globally. It created the world's first approved monoclonal-antibody biosimilar, Remsima (infliximab), and has since built an integrated model. That model spans antibody R&D, global clinical development, regulatory affairs, large-scale mammalian-cell manufacturing in Songdo and now New Jersey, and, since the December 2023 absorption of Celltrion Healthcare, direct global commercialization. FY2025 revenue reached a record KRW 4.16 tn with operating profit of KRW 1.17 tn. Through Q3 2026 the company is running ahead of its KRW 5.3 tn revenue / KRW 1.8 tn operating-profit guidance. Growth is driven by a "young" portfolio of higher-margin products sold mainly through its own direct-sales network. Those products are Remsima SC/Zymfentra, Yuflyma, Vegzelma, Steqeyma, Omlyclo, Stoboclo/Osenvelt, Avtozma and Eydenzelt. Celltrion is now attempting a second transformation into novel antibody-drug conjugates, multispecifics and obesity peptides, alongside a US-anchored CDMO business. --- **What the company does.** Celltrion develops, manufactures and commercializes biopharmaceuticals, overwhelmingly monoclonal-antibody and fusion-protein biosimilars. Its main focus areas are immunology/autoimmune disease (infliximab, adalimumab, ustekinumab, tocilizumab, omalizumab), oncology (rituximab, trastuzumab, bevacizumab, and pembrolizumab and daratumumab in development), bone health (denosumab) and ophthalmology (aflibercept). Through its listed subsidiary Celltrion Pharm (KOSDAQ: 068760, approx. 54–55% owned), it also manufactures and sells chemical (small-molecule) drugs in Korea. Celltrion Pharm also provides prefilled-syringe (PFS) contract manufacturing and sells biosimilars domestically. A third activity, contract manufacturing (CMO/CDMO), became material in 2026 after the acquisition of Eli Lilly's Branchburg, New Jersey facility, which came with a four-year CMO contract worth approx. USD 473 mn. **Company's own description (paraphrased from public disclosures).** The company describes itself as a global biopharmaceutical company with integrated capabilities across the value chain: research, clinical trials, regulatory affairs and large-scale manufacturing. It highlights its first-mover position in antibody biosimilars and a strategic transition toward next-generation innovative therapeutics built on its antibody expertise (company materials and JPM 2026 presentation, January 13, 2026). **Business model and revenue model.** **Value-chain position.** Celltrion is fully vertically integrated from cell-line development to patient-facing sales. The merger with Celltrion Healthcare in December 2023 removed the former two-company structure. Under that structure, Celltrion manufactured and sold product to Celltrion Healthcare, which held inventory and marketed globally. That arrangement was the root of the related-party and inventory-valuation controversies of 2018–2022. Direct sales now capture the full margin. Management states that most newer products are sold through its own direct-sales infrastructure at higher margins than partner sales (Dailypharm, July 28, 2026). **Customer types.** Hospital tender bodies and national/regional procurement agencies (especially in Europe); hospitals and specialty clinics; specialty pharmacies, wholesalers and PBMs/insurers in the US (e.g., Optum's preferred-drug-list listing of Omlyclo from Q4 2026); retail pharmacies in France via Gifrer's network of over 9,000 pharmacies and roughly 800 hospitals; and pharma companies as CMO clients (Eli Lilly; Teva was a CMO customer in 2023). **End-markets.** Immunology (IBD, RA, psoriasis, asthma/allergy), oncology (hematologic and solid tumors), osteoporosis/bone metastasis, ophthalmology (nAMD), and, in development, multiple sclerosis (ocrelizumab), multiple myeloma (daratumumab), immuno-oncology (pembrolizumab), obesity, and novel ADC/multispecific oncology. **Independent characterization.** Celltrion is best understood as a scale manufacturer turned direct-to-market biosimilar commercial platform, with an increasingly differentiated "biobetter" element. Remsima SC was converted into a novel US product (Zymfentra) under a full BLA, and the company has developed high-concentration and liquid formulations. The investment case has shifted from capacity-driven export growth (pre-2020) to margin recovery post-merger (2024–2026). The next phase is optionality in novel drugs and CDMO. Profitability is highly sensitive to product mix: legacy versus "young" products, and direct versus partner sales. It is also sensitive to cost of goods, driven by titer improvement, plant utilization and in-house versus outsourced drug substance.

Revenue$2.9B
Employees2,995
Market CapN/A
Founded2002
Incheon, South Korea
Celltrion

Celltrion Healthcare Co., Ltd.

Premium
Information Technology

Celltrion is South Korea's largest biosimilar developer and exporter and one of a small group of vertically integrated global biosimilar players. It develops, manufactures and directly commercialises monoclonal-antibody and recombinant-protein biologics. The December 2023 absorption of Celltrion Healthcare removed a two-tier structure in which the manufacturer sold product to an affiliated distributor. It also brought global direct-sales networks in Europe and the US inside a single P&L. The franchise was built on the first mAb biosimilar, Remsima (infliximab), which still leads European infliximab. Growth is now driven by a "young" portfolio: Remsima SC/Zymfentra, Yuflyma, Vegzelma, Steqeyma, Omlyclo, Stoboclo/Osenvelt, Avtozma and Eydenzelt. These products exceeded 60% of biologics revenue in 2026. FY2025 revenue was KRW 4.16 trillion and operating income KRW 1.17 trillion, both company records. Management is now adding US manufacturing (Branchburg, NJ), CDMO services, French pharmacy distribution (Gifrer) and an early-stage novel-drug pipeline (ADCs, multispecifics, obesity). --- **What the company does.** Celltrion researches, develops, manufactures and sells protein-based therapeutics. The core of the business is biosimilars, which are near-copies of off-patent originator biologics. Products are concentrated in immunology (TNF-α, IL-12/23, IL-6, IgE inhibition), oncology (CD20, HER2, VEGF), bone health (RANKL) and ophthalmology (VEGF-trap). It also has a proprietary new-drug franchise (Zymfentra, a subcutaneous infliximab approved in the US as a new biologic), a chemical-drug and consumer-health arm (via the KOSDAQ-listed subsidiary Celltrion Pharm, ~53.8% owned, and the newly acquired French company Gifrer), and an emerging contract manufacturing (CMO/CDMO) business. **Company's own characterisation (paraphrased).** In FY2025 and 2026 disclosures, Celltrion presents itself as a global biopharmaceutical company. It says its strategy combines high-margin new biosimilars, structural cost reduction (titre improvement, depletion of pre-merger high-cost inventory, end of development-cost amortisation) and reinvestment of biosimilar cash flow into follow-on biosimilars and novel drugs (Celltrion Q2 2026 results release, Jul 2026; FY2025 release, Feb 2026). MarketScreener's summary of the business report describes operations as a Bio Pharmaceutical segment producing and selling protein therapeutics, alongside other (chemical/other) activities. **Business and revenue model.** **Product sales (dominant):** In FY2025, biopharmaceutical product sales were KRW 3,864.0bn, or 92.8% of consolidated revenue of KRW 4,162.5bn (Meritz Securities, Feb 2026; Celltrion FY2025 release). **Non-biologics (chemical drugs, CMO, other):** KRW 298.6bn in FY2025 (Meritz, derived). This includes Celltrion Pharm's chemical drugs (e.g., Godex, Dilatrend) and contract-manufacturing revenue. **CMO/CDMO services (rising):** A multi-year contract-manufacturing agreement with Eli Lilly began contributing at the Branchburg plant in 2026. Reported value is about USD 473m (American Pharmaceutical Review) or about KRW 678.7bn over three years (Linkareer company summary). Korea Herald reports a four-year contract period. CDMO sales and project management sit in the subsidiary Celltrion BioSolutions, established in 2024 (BioSpectator, Dec 2025). **Licensing / milestone income:** Not a material reported line in the sources reviewed. **Subscription:** Not applicable. **Value-chain position.** After the merger, Celltrion is fully integrated: cell-line development, process development, drug-substance manufacturing (Songdo Plants 1–3; Branchburg, NJ), clinical development, regulatory filings, and direct commercial operations in Europe, North America and other markets. Celltrion Pharm adds domestic distribution and prefilled-syringe (PFS) fill-finish capacity. Gifrer adds French pharmacy distribution. **Customer types.** - Hospitals and hospital purchasing groups, including national and regional tenders in Europe. - US specialty pharmacies, distributors and integrated delivery networks. Access depends on formulary listings with pharmacy benefit managers (PBMs) and insurers; Celltrion reports more than 90% coverage for Zymfentra (Herald Corp, Sep 2026). - Government payers (European national health systems; US Medicare/Medicaid indirectly). - Retail pharmacies (France via Gifrer; Germany for SC products). - Pharmaceutical companies buying CMO services (Eli Lilly). **End-markets served.** - Autoimmune/inflammatory disease: IBD, rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis. - Oncology: NHL/CLL, HER2+ breast and gastric, colorectal, NSCLC. - Allergy/immunology: asthma, chronic spontaneous urticaria, food allergy. - Osteoporosis and skeletal-related events. - Retinal disease: wet AMD, DME, RVO. - Hepatology and cardiovascular (chemical drugs, Korea). - Consumer health/OTC (France). **Independent characterisation.** Celltrion is a scale biosimilar manufacturer-marketer that has moved, within roughly three years, from a captive-distributor model to a direct global commercial organisation. FY2024 profitability was depressed by merger accounting: high-cost inventory bought from the old Celltrion Healthcare and purchase-price-allocation amortisation. The underlying earnings power is now visible in quarterly operating margins of 32–34% in Q2–Q3 2026. Key strategic questions are (a) how fast the young portfolio can grow in the US, where PBM economics and private-label competition limit pricing; (b) whether the novel-drug pipeline produces value beyond biosimilars; and (c) governance and capital allocation in a founder-controlled group.

Revenue$2.9B
Employees2,995
Market CapN/A
Founded2002
Incheon, South Korea
Castelbajac

Castelbajac Co., Ltd.

Premium
Information Technology

Hyungji Global is a small-cap Korean fashion company that controls the Castelbajac brand. Castelbajac is a French designer label whose Korean and global trademark rights, together with the former Paris brand-holding company PMJC S.A.S., were assembled by the Hyungji group between 2014 and 2016. The company built a mid-priced, art-driven golf-apparel franchise that peaked at KRW 92.3bn of revenue in 2018. Revenue then contracted for seven straight years to KRW 37.7bn in 2025, with operating losses every year since 2021. Management has since recast the company as the group's "global" platform. That plan rests on five elements: international licensing of Castelbajac (Taiwan, China, Europe, ASEAN), channel diversification into home shopping, B2B and wholesale, a fintech/payments project (Hyungji Pay and a proposed stablecoin), and the March 2026 acquisition of footwear and handbag affiliate Hyungji Esquire. Operating results turned positive in H1 2026. Even so, the company is on a delisting watch, carries going-concern-style liquidity stress at the parent level, and has a capital structure heavily diluted by mezzanine financing. --- **What the company does.** Hyungji Global designs, sources and sells golf apparel and golf goods under the Castelbajac brand, almost entirely in Korea. Since April 2026 it has also consolidated the footwear and handbag business of Hyungji Esquire (brands Esquire, Portfolio, Sonovi) [S13][S14]. Product mix by revenue line: - Merchandise and products (apparel and accessories): about 98% of revenue in Q2 2026 [S6]. - "Other" (royalties and miscellaneous): about 2% [S6]. Export/overseas revenue is negligible. In FY2025, domestic sales were KRW 374.4억 and exports KRW 2.4억 of KRW 376.8억 total, so exports were about 0.6% [S9]. **Business model.** The company is an asset-light brand owner and merchandiser rather than a manufacturer. PP&E was only KRW 51.7억 at end-2025, against inventory of KRW 197.0억 [S10]. It sources finished goods, sells through consignment-style department-store concessions and franchised agency stores, and earns licensing royalties abroad. Department-store economics dominate its cost structure. Selling commissions (판매수수료) were KRW 93.6억 in FY2025, about 25% of revenue, and are the single largest SG&A item [S9]. **Revenue model mix.** No disclosed breakdown separates product, licensing and service revenue. Two data points bound it: - Merchandise is about 98% of revenue [S6]. - Overseas activity is run mainly through licensing and distribution partners rather than owned retail. That was the company's stated strategy at IPO: grow abroad through licences first and take equity stakes later [S40]. Licensing royalties are therefore likely to fall within the ~2% "other" line, but that is an inference, not a disclosed figure. **Channel mix (H1 2026, consolidated)** [S14]: **Value-chain position.** The company sits at the brand-ownership and merchandising end of the chain. It holds the trademark (industrial-property intangibles of KRW 63.8억 at end-2025 [S10]), controls design direction, and outsources production. Distribution is in-house domestically (concessions and agency stores) and partner-led abroad: - Taiwan: King Bon, via department-store counters including Mitsukoshi [S1][S30]. - China: 100golf, a leading golf e-commerce and retail platform [S4]. - Europe: Prolmeco, from September 2026 [S16]. - ASEAN: Central Group (Thailand), via a May 2023 MOU [S5]. **Customer types and end markets.** The customer base is mainly Korean retail golfers in their 30s to 50s. At launch the brand targeted younger golfers in their 30s and 40s with mid-priced product [S4]. Women golfers were a key growth cohort in the IPO-era market narrative [S35]. Newer customer groups include: - Corporate and institutional buyers of uniforms and gift goods ("법인영업," KRW 64억 in H1 2026) [S14]. - Home-shopping audiences [S14]. - Through Esquire, mass-market footwear and handbag consumers [S13]. **The company's own description.** The FY2025 annual report's business section could not be accessed directly. In public communications the company describes itself as follows [S2][S16]: - A global fashion company and the Hyungji group's "beachhead" for overseas expansion. - A brand that combines French-origin designer artistry with K-fashion vitality. - An entity whose mission includes helping affiliates such as Hyungji Elite (school uniforms) enter China and ASEAN. At its 2019 IPO, management described Castelbajac as a "French original" total-fashion brand that aimed to grow from golf into sports-casual and lifestyle categories, in the mould of Fila Korea [S40]. **Independent characterisation.** In economic substance, Hyungji Global is a sub-scale, single-brand Korean golf-apparel business in structural decline. It is now being used as a holding vehicle within a financially stretched family group. Three facts support this: - Its core revenue fell 59% from the 2018 peak (KRW 923억) to 2025 (KRW 377억) [S40][S7]. - Its standalone workforce has shrunk to 24 people [S12]. - Its 2025–2026 actions are as much capital-structure and group-structure moves as operating moves: rights issues, CB issuance, absorbing the loss-making affiliate Esquire, and lending KRW 156억 to capital-impaired affiliates [S13][S20]. H1 2026 operating profitability is real but modest at KRW 8.8억, and was flattered by the Esquire consolidation [S15].

RevenueN/A
Employees24
Market CapN/A
Founded2016
Incheon, South Korea
Cashbuild

Cashbuild Limited

Premium
Information Technology

Cashbuild is South Africa's largest specialist cash-and-carry retailer of building materials, selling cement, bricks, roofing, steel, plumbing, electrical, tools and related products to a predominantly cash-paying, lower-to-middle-income customer base. Its core customers are owner-builders, home improvers, small contractors, farmers and traders, many in townships, peri-urban and rural areas where formal hardware competition is thin. At 28 June 2026 the group traded from 317 stores across South Africa, Namibia, Botswana, Lesotho and eSwatini, after exiting Zambia (2022) and Malawi (December 2025). FY2026 revenue was R12.1 billion, with Cashbuild-branded South African stores contributing about 82% of sales. The group runs a net cash balance sheet, distributes a high share of earnings as dividends, and is now diversifying formats — small model stores, Cashbuild Xtra, Cabifit and the 60.6%-owned Amper Alles chain — while shrinking the underperforming P&L Hardware network. Its operating margin is thin (about 2–3%), so earnings are highly sensitive to consumer affordability. --- ### Company's own description (paraphrased from FY2025/FY2026 SENS results and the Profile Handbook) Cashbuild describes itself as southern Africa's leading retailer of quality building materials and associated products, selling directly to a predominantly cash-paying customer base through its chain of stores. It states that it carries an in-depth, quality product range tailored to the needs of the specific communities each store serves. It identifies its customers as home-builders and home improvers, contractors, farmers, traders and any other customer that needs quality building materials at the best value. It attributes its credibility to a purchasing and inventory policy designed to ensure that customer requirements are always met. The group's tagline is "Quality building materials at the best value." ### Independent characterisation Cashbuild is a pure-play, store-based building materials retailer with no manufacturing, no material wholesale business and no meaningful credit book. Its economic model rests on four elements: 1. **Location-led convenience.** Most stores are positioned in township, rural and peri-urban catchments, close to customers who build incrementally (one room or one project at a time) and cannot easily travel to large-format metro DIY stores. Management has said that suitable shopping-centre sites for its traditional format are becoming harder to secure, which is why seven of the nine stores opened in FY2026 were small or alternative formats (Business Day, 2 September 2026). 2. **Cash-and-carry, everyday low pricing.** The group sells mostly for cash or card, which keeps receivables minimal (about R111 million on R12.1 billion of revenue in FY2026, S&P) and removes consumer credit risk. Customer finance is offered through third parties (Absa pilot from March 2026; Capitec and NHFC through the Zakhelikhaya programme). 3. **Supplier-funded working capital.** Inventory is largely financed by trade payables (inventory R2.04 billion vs. trade payables R1.83 billion at FY2026, S&P). Year-end cash is therefore sensitive to the timing of supplier payment runs, which the company itself flagged in FY2024 and FY2025. 4. **Store-level operating leverage.** Gross margins sit at about 25%, operating expenses consume roughly 22–23% of revenue, and the operating margin is 2–3% in normal years (7–8% in the FY2021–FY2022 pandemic DIY boom). Small changes in like-for-like sales or cost inflation move profits sharply. **Revenue model mix:** effectively 100% product sales (retail). No subscription or licensing revenue is disclosed. Interest income on cash balances (R111 million in FY2026, S&P) is a material contributor to pre-tax profit relative to the size of operating profit. **Value-chain position:** downstream retail. The group buys from cement producers, brick makers, steel and roofing suppliers, paint and hardware manufacturers and importers, and sells to end users. Several private or exclusive brands are noted (Profile lists Champion Cement and Champion Paint among its popular brand names). **Customer types:** owner-builders and home improvers (the "retail" shopper), small contractors and informal builders (the "bakkie builder"), farmers, small traders. Management noted in FY2025 that the customer mix shifted towards retail shoppers and away from bakkie builders, which reduced the average basket from R737 to R729 (FY2025 results commentary). **End-markets:** residential new-build (incremental self-build), residential renovation and maintenance, small-scale commercial and agricultural construction, informal-sector building, and backup power and water products (inverters, generators, tanks) linked to South Africa's electricity and municipal service failures.

Revenue$0.7B
Employees6,295
Market CapN/A
Founded1978
Johannesburg, South Africa
Carriesoft

Carriesoft Co., Ltd.

Premium
Information Technology

Episode Company is a small-cap Korean content-IP group in the middle of a fundamental pivot. As Carriesoft, it grew from a 2014 YouTube toy-play channel ("Carrie and Toys") into a children's and family entertainment brand built around the "Carrie and Friends" characters, with YouTube, IPTV, theatrical animation, musicals, merchandise and kids' cafés. That legacy business shrank from KRW 10.1 billion in revenue (FY2022) to KRW 5.7 billion (FY2025) and posted operating losses every year. Between December 2025 and January 2026, management bought: - Ace Factory, a drama producer and actor agency whose roster includes Lee Jong-suk; and - a majority stake in Studio Episode, a web-content and IP-commerce studio. The group then renamed itself to signal a move from infant-focused content toward an all-ages "IP universe." Trailing revenue jumped to about KRW 37 billion as a result. The company is still loss-making and dependent on equity issuance, so execution and dilution are now the central investment questions. --- ### Company's Own Description In its February 2026 rebranding announcement, the company said the name change reflects its intent to move beyond a structure centred on infant and toddler content. It aims instead to build an IP universe spanning all generations and genres for the global market. The new name rests on the slogan "Connection becomes a universe." The company wants to be an "IP value-up platform" that extends the life and value of each IP, rather than a distributor of standalone content (Sports Kyunghyang, 26 Feb 2026). The current KOCCA/WelCon profile (as of April 2026) describes the company as: - developing and commercialising IP; - producing and investing in 3D animation, live-action films and television dramas; - operating its own animation studio; and - holding subsidiaries including Ace Factory, Studio Episode and Carrie TV, distributing content and IP through distributors, video platforms and broadcasters worldwide. ### Reported Business Lines (Pre-Rebrand Structure) | Business | What it contains | |---|---| | Content IP business | Merchandising (MD) products, licensed products, commerce, performances (family musicals) and kids' cafés | | Content business | Broadcast video programme production, animation distribution-rights sales, VOD sales, advertising sales and sponsorship sales | MarketScreener/S&P Capital IQ describe two businesses. S&P's segment data for FY2021–FY2024 uses a slightly different cut: - Content Creation and Distribution (Domestic); - Content Creation and Distribution (Asia); - Advertising Agency (Domestic); and - consolidation eliminations. ### Independent Characterisation From FY2021 to FY2025 the group was a micro-revenue IP licensor and content producer with a very light physical footprint. Standardised gross margins were reported at 88–99%. This reflects S&P's classification, which places most production costs within SG&A rather than cost of revenue. Persistent operating losses of about KRW 2.1–3.8 billion a year show that the true cost base was far larger than the revenue base. Revenue came from four sources: 1. **Platform-driven advertising and VOD income**: YouTube channels, Carrie TV on IPTV/cable/OTT, and Chinese video platforms. 2. **Licensing and merchandise**: a 2019 interview cited about 400 character products. 3. **Live performances and kids' cafés.** 4. **An advertising-agency subsidiary**, contributing about KRW 2.0–2.3 billion a year. **Value-chain position.** The company is an IP originator and producer. It sits upstream of platforms (YouTube, IPTV operators, broadcasters such as MBC, Chinese OTT services) and licensees, and downstream of nothing material. **Revenue-model mix.** - Product revenue (MD/commerce) - Service revenue (performances, cafés, advertising agency) - Licensing and distribution rights - Platform advertising and VOD The company does not disclose a precise mix by revenue type. **Customer types.** - Consumers: parents of children aged roughly 2–9, plus K-drama and celebrity-content audiences after 2026 - Platforms and broadcasters - Licensees and retailers - Advertisers (agency business) **End-markets.** - Korean children's content and character merchandise - Korean drama production and talent management (via Ace Factory, from 2026) - Korean web/creator content and IP commerce (via Studio Episode, from 2026) - Limited exposure to China and Southeast Asia **Post-2026 model.** A "federated" holding structure: **Ace Factory:** premium scripted drama and actor management. **Studio Episode:** celebrity- and lifestyle-led web content and commerce. **Parent (Episode Company):** owns and manages the IP library and applies AI tools to production (Sports Kyunghyang, Feb 2026).

Revenue$0.0B
Employees47
Market Cap$0.0B
Founded2014
Seoul, South Korea
Caregen

Caregen Co., Ltd.

Premium
Information Technology

Caregen is a Korean, founder-controlled, export-oriented developer and manufacturer of synthetic biomimetic peptides and recombinant growth factors. Its commercial base is a high-margin portfolio of peptide-enhanced dermal fillers, mesotherapy products and cosmeceuticals sold through exclusive or non-exclusive distributors in roughly 130 countries, with exports historically around 95–98% of revenue. Since 2022 it has used the same peptide library to build an oral "metabolic health" franchise — ProGsterol (glucose), MyoKi (muscle) and Korglutide (a GLP-1/IGF-1 dual-acting weight-management peptide) — registered as dietary ingredients via US FDA NDI notifications rather than as drugs. A drug pipeline led by CG-P5, a topical peptide eye drop for wet AMD that completed a US Phase 1 study, provides option value. The investment case has swung sharply in 2025–26: record contract announcements and a KRW 7.7tn peak valuation have been followed by earnings dilution, Middle East receivable write-downs, contract terminations and a 75%+ share-price decline. --- ### Company's own description (Q3 FY2024 quarterly report, paraphrased) Caregen describes itself as a company that, based on research into biomimetic peptides and growth factor proteins, develops and sells pharmaceuticals, health functional foods, medical devices and cosmetics. Peptides are produced by chemical synthesis at scale; growth factors are produced by genetic engineering. The company states it has built a peptide library protected by more than 730 registered domestic and overseas patents (Sep 2024), and sells "professional therapy" products (fillers, mesotherapy) and functional cosmetics incorporating its peptides, dual-encapsulation and sustained-release technologies in about 130 countries. It describes its planned new businesses as antiviral (COVID-19) medicines, macular-degeneration medicines, and animal medicines and functional feed. The company notes it started in 2001 developing protein chips for cancer diagnosis, pivoted from 2003 to growth factors and biomimetic peptides for devices and cosmeceuticals, and from 2022 entered health functional foods. ### Independent characterisation **Business model:** Vertically integrated peptide platform — discovery (library of 1,200+ proprietary peptides per the company's BIO USA profile), in-house synthesis (Hwaseong peptide plant, 10 tonnes/year design capacity), finished-goods manufacture (Gunpo plants 1 and 2), and B2B export to country distributors. Distribution partners typically bear local registration costs and timelines (Dealsite, 2023 company interview). **Revenue model:** Overwhelmingly product sales (devices, cosmeceuticals, dietary supplements, bulk ingredients). Licensing revenue: none disclosed. The Q3 FY2024 report states the company had no licence-out, licence-in or technology-alliance contracts. Long-term "supply agreements" announced in the press are frequently framework or non-binding agreements whose value depends on partner orders — a structural feature that has repeatedly produced gaps between headline contract values and booked revenue. **Value-chain position:** Upstream (API/ingredient) through finished product; no direct-to-consumer retail of note; no domestic Korean sales of the peptide supplements (the company has said Korean regulators do not recognise synthetic peptides as health-food ingredients — Dealsite, Aug 2025). **Customers:** Country distributors, aesthetic clinics (indirectly), pharmaceutical and nutraceutical distributors (e.g., IFA Celtics Mexico, Atabay Türkiye, Li Shizhen Pharmaceutical China, 2San USA), and cosmetics brand owners for raw peptides (e.g., BASF supply agreement, 2020). **End-markets:** Medical aesthetics (fillers, mesotherapy, hair-loss), cosmeceuticals, dietary supplements (glycaemic control, weight management, sarcopenia), and, prospectively, ophthalmology (wet AMD, dry eye) and drug delivery (Luxidase platform).

Revenue$0.1B
Employees209
Market CapN/A
Founded2001
Anyang, South Korea
Capitec

Capitec Limited

Premium
Information Technology

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---|---| | Employees (number) | 14758 | 15451 | 15747 | 16935 | 17672 | Capitec Limited is South Africa's largest bank by client numbers and its most profitable large bank on a return-on-equity basis, serving 26.6 million active clients through 895 branches, more than 9,000 cash devices and a banking app used monthly by 16.5 million people (H1 FY2027). Born as a PSG-backed micro-lender and licensed as a bank in 2001, it built its franchise on a single, low-fee transactional account and risk-priced unsecured credit for mass-market South Africans. Over the past five years it has transformed into a diversified financial-services platform: non-interest income now makes up 70% of income from operations after credit impairments, generated by transaction fees, value-added services (prepaid airtime, data, electricity, "send cash"), its Capitec Connect mobile virtual network, a fast-scaling business bank and an in-house life insurer. A small European/Mexican online lender (AvaFin) is its only foreign operation. The August 2026 renaming to "Capitec Limited" formalises its "more than a bank" strategy. --- ### What the company does Capitec is a vertically integrated, mass-market retail and SME financial-services group operating almost entirely in South Africa. It runs four reportable operating segments: Personal Banking (including the separately discussed Fintech sub-business of Value-Added Services and Capitec Connect), Business Banking, Insurance (Capitec Life) and AvaFin (foreign online consumer lending). The CODM (Group Executive Committee headed by the CEO) reviews these four segments monthly (FY2026 segment note). **Company's own description (paraphrased from the FY2026 summary financial statements and H1 FY2027 interims).** Capitec describes itself as a business that delivers simple, transparent and affordable financial solutions at scale, grounded in four fundamentals — simplicity, affordability, accessibility and a personalised experience — and increasingly extending "beyond traditional banking" into everyday client needs such as connectivity, Smart ID applications, stokvel savings and device sales. Its stated purpose is to make a meaningful difference in clients' financial lives and help South Africans grow. **Independent characterisation.** Capitec is best understood as a low-cost, high-volume consumer platform with three earnings engines layered on a single client base: (1) a deposit-and-transaction franchise that monetises ~12.3 billion annual transactions through small per-transaction fees and interchange; (2) a high-yield, high-loss unsecured lending book (Term Loans, Access Facility, Credit Card) priced within National Credit Act caps and supported by a very large liquid investment portfolio; and (3) capital-light annuity businesses (VAS, funeral/credit-life insurance, MVNO) that now generate roughly 60% of group earnings. Its competitive moat is the combination of the largest physical distribution network among SA retail banks by client reach, a sector-leading digital app base, the lowest-cost fee structure among the incumbents, and a data asset across 26+ million clients used for credit scoring and targeted offers. ### Business and revenue model (FY2026, R'm, computed shares of total operating income before impairments of R52,420m) | Revenue line (FY2026) | R'm | Share of total operating income (%) | |---|---|---| | Net interest income | 24079 | 45.9 | | — of which interest income on lending (gross) | 24140 | — | | — of which interest income on investments (gross) | 9169 | — | | Net transaction and commission income (incl. VAS and Capitec Connect) | 21525 | 41.1 | | — of which VAS | 5650 | 10.8 | | — of which Capitec Connect | 442 | 0.8 | | Net insurance result | 5224 | 10.0 | | Net loan fee income | 1437 | 2.7 | | Net foreign currency, dividend and other income | 155 | 0.3 | | Total operating income before credit impairments | 52420 | 100.0 | Source: FY2026 audited summary consolidated financial statements; shares computed. **Model mix interpretation.** Capitec has no "product vs service vs subscription vs licensing" split in the industrial sense. Mapped to that framework: (a) "product" revenue = lending (interest + loan fees, ~48% of operating income); (b) "service/transaction" revenue = transaction fees, interchange, VAS commissions (~41%); (c) "subscription-like" revenue = monthly account fees (R7.50 Main Account fee) and recurring insurance premiums (net insurance result ~10%); (d) licensing revenue = none disclosed. ### Value-chain position Capitec occupies the full retail-banking value chain: client acquisition (branches, app, sales consultants), deposit-taking, credit origination and collections, payments processing (Capitec Payment Services, Capitec Pay, merchant acquiring), insurance manufacturing and underwriting (Capitec Life licence since October 2022), and telecom resale (MVNO on Cell C's network). It relies on third parties for card schemes, national payment rails (PayShap/PayInc), mobile network infrastructure (Cell C), cross-border remittance rails (Mama Money), mortgage origination support (SA Home Loans), digital wallets (Apple, Google, Samsung, Garmin) and cloud computing. ### Client types and end-markets | Client segment | Scale (latest) | Source | |---|---|---| | Personal Banking active clients | 25.7m (Aug 2026); 25.2m (Feb 2026) | H1 FY2027; FY2026 | | Fully banked (main-banked) personal clients | 10.4m, 41% of active clients (Aug 2026) | H1 FY2027 | | Active banking app clients | 16.5m (Aug 2026) | H1 FY2027 | | Young clients aged 18–25 | Almost 5m | CEO comments, H1 FY2027 press release | | Business Banking clients (all, incl. Entrepreneur accounts) | 686,000, of which 237,000 Entrepreneur accounts; 141,000 merchant accounts (Aug 2026) | H1 FY2027 press release | | Business Banking active clients incl. card-machine merchants (narrower definition) | 383,068 (Feb 2026) | FY2026 | | Capitec Connect active clients (3-month) | 1.8m (Aug 2026) | H1 FY2027 | | Credit Life policies | 2.2m | H1 FY2027 | | Funeral policies / lives covered | 3.8m policies / 17.1m lives | H1 FY2027 | | Capitec Pay unique clients | 12.5m (H1 FY2027) | H1 FY2027 | | AvaFin unique clients | ~200,000 (Aug 2026), down from 250,000 | H1 FY2027 | End-markets: South African mass-market and middle-income consumers (core), informal and small businesses, SMEs and commercial clients (Business Banking), e-commerce merchants (Capitec Pay), and sub-prime online borrowers in Poland, Czechia, Spain, Latvia and Mexico (AvaFin).

RevenueN/A
Employees17,741
Market CapN/A
Founded1997
Stellenbosch, South Africa
CAMUS

CAMUS ENGINEERING & CONSTRUCTION Inc.

Premium
Information Technology

CAMUS E&C is a mid-sized Korean general contractor built around a niche manufacturing capability: precast concrete (PC). The company brought French engineer Raymond Camus's precast system to Korea in the late 1970s. It now produces columns, beams, slabs and wall elements at plants in Icheon and Cheonan, and in September 2026 it added an acquired plant in Eumseong. It erects these elements on large logistics centres, semiconductor fabs and public works. Since 2024 the business has been pulled decisively toward SK hynix's fab programme in Cheongju and Yongin. This has turned a loss-making general builder (FY2024 net loss KRW 21.9bn) into a profitable one (FY2025 net income KRW 20.0bn; H1 2026 revenue +82% YoY). A second, smaller leg came from the 2023–24 acquisition of Korea Aluminium (한국알미늄), a maker of aluminium foil and battery pouch film, which accounts for about 18% of revenue. The company is controlled by the privately held Base Group. It trades at roughly 3–4x trailing earnings and below book value. --- ### Company's own description (paraphrased from filings and company statements) In its filings and press material, the company describes itself as a general construction company with three activities [S18][S19][S20]: 1. **General construction (종합건설업)**: building and civil works. 2. **Manufacture and sale of PC products (PC제품 제조·판매)**: manufacture and installation of precast components. 3. **Real-estate leasing (부동산임대업)**. Its business-report summary, as reproduced by Korean Wikipedia, says it uses the PC method on large logistics centres, factories and building façades, and that it has expanded into general building, apartment construction, housing sales and civil engineering. The PC business manufactures columns, beams, slabs and walls in the factory, then transports and installs them on site. The main applications are logistics centres, semiconductor plants and underground car parks [S19]. Following the Korea Aluminium acquisition, consolidated reporting also includes a manufacturing segment for aluminium foil and related products (은박지 및 포일 제조) [S10]. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Almost entirely project/contract revenue recognised over time (percentage-of-completion) for construction and PC supply-and-install contracts. Product revenue comes from aluminium foil and pouch-film sales through Korea Aluminium. Minor rental income. No subscription or licensing revenue identified. | | Product vs. service mix | Mostly "product-embedded service": PC elements are manufactured in-house and sold under supply-and-installation contracts. In August 2024 the company said PC manufacturing made up 40–60% of revenue [S21]. In 2017, PC-related revenue was 63% of the total [S17]. | | Payment terms | Large PC contracts are typically paid as progress billings without down-payments. The 2026 Yongin Ph-4 FAB contract has no deposit or advance and is billed on progress [S13]. | | Value-chain position | Tier-2 specialist subcontractor to EPC/general contractors (notably SK ecoplant for SK hynix fabs). Also a prime contractor on public building/housing (LH, KEPCO) and private logistics/knowledge-industry-centre projects. | | Customer types | Semiconductor makers (via their EPC arms), logistics developers and PFVs, public agencies (LH, KEPCO), hospitals and foundations, industrial and pharmaceutical/food packaging buyers (aluminium). | | End-markets | Semiconductor fab construction; logistics/warehouse; public housing and buildings; civil infrastructure (airports, rail, waterways, wastewater); packaging (food/pharma); lithium-ion battery materials (pouch film). | ### Independent characterisation CAMUS has three businesses of very different quality inside one listed shell: **The PC franchise:** is the economic core. Precast fab shells have become the default structural method for Korean memory-fab super-structures and utility buildings, and CAMUS is one of a small number of domestic suppliers with the plant capacity, engineering references and SK-group relationships to deliver them at scale. Its references include SK hynix M16 Icheon (2018–2020), M15 WWT, M15X Cheongju, Yongin Y1 WWT/UT, Cheongju P&T7 and Yongin Ph-4 FAB [S14][S16][S24][S25]. **The general-building/housing arm:** caused most of the 2022 and 2024 losses. It carried private-housing receivables, unsold completed units and PF completion guarantees. Management says it has largely stopped private self-developed housing and now concentrates on public works [S14]. **Korea Aluminium:** is a diversification move by the controlling group. Its standalone performance is weak (most recent fiscal year: total assets KRW 38.8bn, net loss KRW 2.4bn) [S8]. Strategically it gives the group exposure to battery pouch film and foil packaging, but it has no operating synergy with construction. The investment case is therefore essentially a leveraged bet on SK hynix's Korean capex cycle, delivered through a thinly traded, majority-controlled vehicle.

Revenue$0.2B
Employees159
Market CapN/A
Founded1978
Icheon, South Korea
Campine

Campine NV

Premium
Information Technology

Campine NV is a Beerse-based, Hempel-family-controlled specialty chemicals and circular metals group that has evolved from a regional lead-battery smelter into the world's leading producer of antimony trioxide (ATO) outside — and, since China's 2024 export restrictions, arguably including — China. Its two divisions are tightly integrated: the Circular Metals division recycles lead-acid batteries and metallurgical residues into lead alloys and recovers tin, antimony, silver and gold; the Specialty Chemicals division converts antimony (partly self-recycled via proprietary technology the company describes as unique worldwide) into ATO for flame retardants and PET catalysts, flame-retardant masterbatches, and recycled polypropylene sourced from battery casings. Two bolt-on acquisitions in France (Recylex assets 2022, Ecobat France 2025) made it Europe's second-largest lead battery recycler, and the pending Flamaway deal (2026) broadens it into multi-chemistry flame-retardant formulations. Earnings are highly leveraged to antimony and LME lead prices. --- ### What the company does Campine operates a vertically integrated "urban mining" model. Spent automotive and industrial lead-acid batteries are collected, broken and separated in battery-breaking plants (Beerse and France). The lead-bearing paste and grids are smelted and refined into lead and lead alloys (Beerse produced approximately 61,000 tonnes of lead alloys in each of 2023, 2024 and 2025 [PR-FY23], [PR-FY24], [PR-FY25]), sold principally to battery manufacturers. The polypropylene (PP) casings feed Campine's recycled Polymers (CrP / rP) unit. Antimony contained in lead alloys and other industrial waste streams is captured by Campine's proprietary antimony recycling process and fed into the Specialty Chemicals division, where it is converted to antimony trioxide — a synergist in halogenated flame-retardant systems and a polymerization catalyst for PET. ATO is also compounded into flame-retardant masterbatches (FRMB) sold to plastics converters. ### Company's own description In its FY2025 results release, the company defines the Specialty Chemicals segment as the business units Antimony Trioxide (ATO), Flame Retardant Masterbatches (FRMB) and recycled Polymers (rP); and the Circular Metals segment as the business units Lead (Pb), Metals Recovery (MR), recycled Batteries (rB) and Le Plomb Français (LPF) [PR-FY25]. Data providers summarise the company (likely drawing on the annual report) as follows: Specialty Chemicals hosts all businesses that serve end-markets with chemical products and derivatives; Circular Metals hosts the businesses that recover metals from industrial and post-consumer waste streams, with lead alloys as the main activity (Morningstar profile). Since 2026 the company has styled itself in press releases as a "Belgian specialty chemicals and circular metals company" [PR-FY26H1] — note the reordering, which places specialty chemicals first. ### Revenue model | Revenue type | Share of mix | Comment | |---|---|---| | Product sales (metals, alloys, chemicals, masterbatches, recycled PP) | ~100% | Campine is a pure product-sales business; pricing is formula-based on reference metal prices (antimony metal for ATO; LME lead for alloys) plus conversion premium | | Services (toll processing / recycling fees) | n/d | Gate fees or treatment charges on battery scrap and waste are embedded in purchase-price spreads rather than reported separately | | Subscription / licensing | 0 | No licensing of the proprietary antimony recycling technology has been disclosed | **Independent characterization.** Economically, Campine earns (i) a conversion margin on metals, which widens when battery scrap is abundant and cheap relative to LME lead [PR-FY24]; (ii) an inventory/price-lag effect on antimony, which produced windfall margins in 2024–2025 and inventory write-downs at end-2025 [PR-FY25]; and (iii) an "own-feed" margin from recycled antimony, which substitutes for purchased antimony metal and becomes disproportionately valuable when antimony prices spike. Because revenue is pass-through-priced off metal indices, revenue growth is a poor indicator of value creation; EBITDA per tonne and EBITDA margin are the relevant metrics. ### Value-chain position Campine sits mid-stream: downstream of scrap collectors and battery waste generators, and upstream of battery makers (lead), polymer compounders, PET producers, textile and cable manufacturers (ATO/FR products), and zinc/copper smelters (anodes from Le Plomb Français) [PR-FY25]. ### Customer types and end-markets | End-market | Products | Notes | |---|---|---| | Lead-acid battery manufacturing (automotive SLI, industrial, standby) | Lead and lead alloys | Core Circular Metals outlet | | Plastics / polymer compounding (cables, electrical & electronic housings, construction) | ATO, FRMB | Flame retardancy standards drive demand | | PET resin production | ATO as polycondensation catalyst | Cited explicitly as a key application [PR-FY24-PW] | | Textiles | Flame-retardant formulations (Flamaway, from 2026) | Flamaway "particularly strong" in textiles [PR-FLAM] | | Automotive & consumer plastics | Recycled PP (rP / CrP) | Benefits from EU local-sourcing preferences [PR-FY25] | | Non-ferrous smelting (zinc, copper electrowinning) | Lead anodes (LPF) | Added via Ecobat [PR-FY25], [BI] | | Medical devices, nuclear energy (radiation shielding) | Semi-finished lead products (LPF) | Cited by CEO as diversification [PR-FY25] | | Precious & minor metals markets | Tin, antimony, silver, gold from Metals Recovery | Benefited from high gold/silver/tin prices 2024–2026 |

Revenue$0.9B
Employees307
Market CapN/A
Founded1912
Beerse, Belgium

Page 80 of 482

1…798081…482

Page 80 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo